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Natural products have been an important resource for the maintenance of life for ages.
Already in the earliest written traditions, e.g. the Rigveda of South Asia (ca. 1500-900 BC), it
is evident that plants played an important role in daily life. One of the best-known examples is
Soma, a plant that was pressed to yield juice, which was used as a medicine
(Mukhopadhyaya, 1922-1929, Mahdihassan and Mehdi, 1989). The interest in medicinal
plants has never ceased since. Even today, natural products become increasingly important as
a source of pharmacotherapeutics, either directly, for example in the application of herbal
drugs for the treatment of chronic diseases, or as raw material from which more or less
complex chemical structures with particular biological activity are isolated. Cragg et al.
(1997) reviewed the role of natural products in drug discovery, and concluded that for the
disease indications anticancer and anti-infection, more then 60% of new approved drugs are
derived from natural sources. Furthermore, there is a global concern about emerging
infectious diseases, and an urgent need to identify novel means for effective treatment thereof.
The National Cancer Institute has screened randomly a hundred thousand plant extracts
for antineoplastic, anticarcinogenic, and antitumor activity in several model systems. This
strategy did not prove very effective (Reynolds, 1991). Traditional systems of medicine,
however, provide an extremely vast body of source material for the development of new drugs
(Holland, 1994). Evaluation of traditionally used medicines, keeping into account the
traditional principles that are applied in drug therapy, may supply leads towards effective drug
discovery.
One of the species that emerged from such an inventory is Picrorhiza kurrooa Royle
(Labadie et al., 1989). This plant has been the subject of another thesis, which focused on its
modulatory effects on complement activation and the production of chemiluminescence by
activated neutrophils. Two macromolecules have been isolated that interfered with the
classical pathway and the alternative pathway of complement activation, respectively.
Furthermore, several phenols were isolated that inhibited the production of
chemiluminescence by activated neutrophils. One of these, apocynin, also reduced the
severity of symptoms in experimentally induced arthritis (Simons, 1989, ’t Hart et al., 1990).
Because oxidative stress due to reactive oxygen species is a major contributor to joint damage
in rheumatoid arthritis (Halliwell and Gutteridge, 1999), these data suggest the usefulness of
Picrorhiza in the treatment of this disease. This impelled further research into active
constituents of Picrorhiza that may be modulating immune responses.
Objective
The objective of this thesis was the further pre-clinical evaluation of the
immunomodulatory activity of Picrorhiza and the activity-guided isolation of other active
constituents, in order to assess its usefulness in rheumatoid arthritis or related conditions. This
assessment is presented from a pharmacognostic perspective. The ultimate biomedical goal of
pharmacognosy is “to contribute to the causal and hence rational relationships between the
chemical constituents of medicinal plant preparations and the biological and therapeutic
effects they generate” (Labadie et al., 1989). Traditional systems of medicine provide an
extensive source of material, which may demonstrate such relationships. To investigate the
nature of these relationships, a multidisciplinary approach is required, ranging from
anthropology, via philology, botany, phytochemistry, pharmacology, to medicine. In this
thesis, several of these fields are taken into consideration in answering questions pertaining to
the usefulness of Picrorhiza in chronic inflammation.
Rhizomes of two Picrorhiza species happen to be available on South-Asian markets: P.
kurrooa Royle and P. scrophulariiflora Pennell (Scrophulariaceae). Both species are known
under the same local name, and used for similar purposes. The material under investigation,
which was obtained from the market, was identified as Picrorhiza scrophulariiflora Pennell
(Scrophulariaceae). This species is categorized into a separate genus by Hong (1984), who
named it “Neopicrorhiza scrophulariiflora”. For reasons of clarity, however, described in
chapter 2, the name Picrorhiza scrophulariiflora is maintained throughout this thesis.
Outline
Chapter 2 deals with taxonomical and geographical information concerning the proper
identity of the plant material used. This chapter is partly based on fieldwork performed in the
Himalaya regions of Nepal and India. Chapter 3 elaborates on the traditional use of Picrorhiza
in Āyurveda, a traditional life science of South Asia, as known from ancient Sanskrit
literature, as well as from contemporary use. Two approaches have been followed, one based
on the direct exploitation of empirical knowledge, and the other on the specific application of
generalized traditional principles. In chapter 4, an overview is given of metabolites that have
been isolated from Picrorhiza, and their biological activity is discussed with regard to
immunomodulation. Chapter 5 gives a limited overview of the background necessary to
understand the assays and models used, and describes the in vitro and in vivo
immunomodulatory activity of Picrorhiza extracts. Chapter 6 describes the activity-guided
fractionation of extracts that interfere with the classical pathway of complement activation.
Activity-guided isolation of two cucurbitacins that inhibit proliferation of activated T
lymphocytes is described in chapter 7, while chapter 8 elaborates on the mechanisms of action
involved. Finally, chapter 9 provides a summary and a general discussion of the topics that
were elaborated in this thesis, and extends the discussion to further perspectives. In addition,
appendices have been included as reference to Sanskrit words and abbreviations.
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Introduction
The present chapter describes taxonomical aspects of species from the closely related
genera Picrorhiza and Neopicrorhiza. Since the plant material used for the experiments
described in this thesis was obtained as simplex, and as there are no discriminative features
between the rhizomes of both species, the identity of the plant material could not directly be
determined. This chapter provides a basis for the proper identification of the plant material
investigated.
Picrorhiza and Neopicrorhiza are small genera belonging to the tribe Veroniceae of the
family Scrophulariaceae. This family is, according to the taxonomical system of Cronquist,
arranged in the order Scrophulariales, subclass Asteridae, class Dicotyledonae, of the
Angiospermae. The genus Picrorhiza was considered monotypic, with as only species P.
kurrooa, until Pennell (1943) distinguished a second species: P. scrophulariiflora (originally
written as “P. scrophulariaeflora”). This new species is brought under a separate genus by
Hong (1984), who named it Neopicrorhiza scrophulariiflora. This name has been accepted as
the official name of this species (Brummit, 1992). However, several arguments are in favor of
the use of the basionym Picrorhiza scrophulariiflora within the scope of this thesis. Firstly,
most literature on this species published after 1984 sticks to this synonym. Secondly, because
of their similarity, rhizomes of both species are comparable with regard to their morphology,
histology, accumulated metabolites, bitterness, activity, and traditional use (Zhang et al.,
1965, Wang et al., 1993). Thirdly, because distinguishing criteria between rhizomes of both
species have not been developed so far, plant material described in publications on biological
activity or constituents as referred to P. kurrooa and obtained from raw material suppliers
might erroneously be mixed up with P. scrophulariiflora. Therefore, the name Picrorhiza
scrophulariiflora is used throughout this thesis.
Discussion
Picrorhiza
The genus Picrorhiza and the species P. kurrooa appeared for the first time on a drawing
published by Royle on August 24, 18351 in his “Illustrations of Botany” (figure 1) (Royle,
1835-1840a). Bentham described the genus and the species in his “Scrophularineae Indicae”,
which was published a few months later, on November 17, 1835 (Bentham, 1835). However,
he wrote the species name as “P. kurroa”, probably correcting or misspelling the name of
Royle’s publication. In May 1836, Royle published the text on Picrorhiza, and retained the
species name “P. kurrooa” (Royle, 1835-1940b). Because Bentham was the first to give a
written description of the species, the accepted species name has been “Picrorhiza kurrooa
Bentham”, or alternatively “Picrorhiza kurrooa Royle ex Bentham”. However, according to
the International Code of Botanical Nomenclature article 42, an illustration with analysis
published before January 1, 1908 is acceptable as valid publication, instead of a written
description or diagnosis (Greuter et al., 1994). Therefore, the correct name of the species is
“Picrorhiza kurrooa Royle”.
                                                          
1 For publication dates see: Stafleu and Cowan, 1983.
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Figure 1. First publication on Picrorhiza kurrooa by Royle in 1835.
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Royle states that the generic name is derived from the bitter root, which is used in native
medicine (Royle, 1835-1940b). In Greek, “picros” means bitter, while “rhiza” means root.
The specific name is derived from “Karu”, the Punjabi name of the plant, which means bitter
as well (Coventry, 1927).
In 1876, Bentham and Hooker described the genus Picrorhiza in their “Genera
Plantarum”, mentioning the existence of only one species. The genus was considered
monotypic until Pennell distinguished another species, based on information in Hooker’s
“Flora of British India” (Pennell, 1943). Hooker considered the flowers of P. kurrooa as
dimorphic, which was so far not known in the Scrophulariaceae. He distinguished a form with
long stamens and a short corolla with five sub-equal lobes, and a form with short stamens and
a bilabiate corolla, of which the upper lip is longer and the lower lip consists of three shorter
lobes (Hooker, 1885).
Smith and Cave collected a Picrorhiza species at the base of the Zemu glacier in Sikkim
at 4300 meter, and identified it as P. kurrooa (Smith and Cave, 1911). There is a specimen at
the Herbarium of the Academy of Natural Sciences of Philadelphia (PH), which was
identified by Pennell as the short-stamened form described by Hooker. Furthermore, he
noticed that all collections seen from the Western Himalaya are in agreement with the form
having long stamens, while those from the eastern Himalaya and Yunnan correspond to the
form with short stamens. Therefore, he characterized two species, one of the dry western (P.
kurrooa), and the other of the moist eastern Himalaya (P. scrophulariiflora) (Pennel, 1943).
Neopicrorhiza
Based on the differences described above, and additional differences between the pollen
of both species, Hong (1984) suggested to place both taxa into two distinct genera: Picrorhiza
and Neopicrorhiza. Both genera are monotypic, including P. kurrooa and P. scrophularii-
flora, respectively. In the former, the corolla is almost actinomorphic with a short corolla tube
and five equal lobes, and with stamens about 3 times longer than the corolla (Hong, 1984).
The name “Neopicrorhiza scrophulariiflora (Pennell) Hong” has been reserved as the official
name of this species (Brummitt, 1992).
Description and distribution
A. Family Scrophulariaceae, tribe Veroniceae, genus Picrorhiza:
Perennial herb, usually with a long rhizome. Leaves basal and alternate. Spikes terminal.
Calyx nearly equally 5-partite. Corolla 4- or 5-lobed, bilabiate with lobes more or less
spreading or nearly actinomorphic. Stamens 4, inserted on corolla tube, slightly
didynamous, as long as corolla or strongly exserted. Stigma capitate. Capsule turgid,
tapered at top, dehiscing first septicidally and then loculicidally into 4 valves. Seeds
numerous, ellipsoid; seed coat very thick, transparent and alveolate. Pollen grains
spheroidal, 3-colpate, with partial or perforate tectum, the partial tectum microreticulate,
colpus membrane smooth or sparsely granular.
1 Corolla 4-5 mm long, 5-lobed, and nearly actinomorphic; stamens many times
longer than corolla. – Picrorhiza Royle
2. Corolla 9-10 mm long, 4-lobed, and bilabiate; stamens slightly didynamous,
equalling corolla. – Neopicrorhiza Hong
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1. Picrorhiza kurrooa Royle, Ill. Bot.: t. 71. 1835; Benth., Scroph. Ind.: 47. 1835; Benth. et
Hook.f. Gen. Plant. 2: 962. 1876; Hook.f. Fl. Brit. Ind. 4: 290. 1885.
Distribution: Kashmir to Kumaon, 3000-4300 m (Pennell, 1943), Pakistan to Uttar
Pradesh, 3300-4300 m (Polunin and Stainton, 1990). Jammu & Kashmir: Apharwat,
Kashmir (Rau, 1975), Burzil Pass, Stewart 18856, 19084, 19224  (Pennell, 1943), Gumri, Vir
Jee 133 (Jee et al., 1987), Kamri Pass (Naigund), Inayat 25732  (Pennell, 1943), Kolohoi;
Zojpal; Sonsa Nag, 10,000-13,000 ft (Coventry, 1927), Lipper Valley, northwest of Kashmir
Valley (Singh and Kachroo, 1976), Mir Panzil Pass, Deosai Road, Stewart 19945a  (Pennell,
1943), Nafran, Stewart 12537  (Pennell, 1943), Pahlgam, Stewart 5839, 7823, 9278 (Pennell,
1943), Pir Panjal range; Krishan Ganga valley; upper Lidder valley (Kapahi et al., 1993),
Pirpanjal range; Krishnaganga Valley; Upper Lidder Valley (Kapil, 1995), Simthan, Jammu
(Sharma and Kachroo, 1981), Sonamarg, Stewart 6417, 6597½  (Pennell, 1943), Tragbal,
Stewart 4618  (Pennell, 1943), Zojibal Pass, Stewart 18234 (Pennell, 1943; Himachal
Pradesh: Basharh: Chhit Kul, Parmanand 1032; Hangla Pass, Parmanand 688; Pieri Pass,
Kinnawar, Parmanand 521 (Pennell, 1943), Chafuwa, Talla Johar, Eastern Kumaon, 3500 m
2126 (Mehta et al., 1994), Chamba and Kangra (Gammie, 1898), Chamba: Kukti Pass, Koelz
8600  (Pennell, 1943), Chamba; Kinnaur; Kulu; Lahul; Spiti (Chowdhery and Wadhwa,
1984), Chhakinal watershed, District Kullu (Dobriyal et al., 1997), Kangra (Kulu):
Chandrokani, Koelz 61; Sumdo, Koelz 5011 (Pennell, 1943), Lahaul; Kinnaur; Kulu; Rohru;
Kangra; Pangi-Bharmour above 3500 m (Chauhan, 1988), Lahul: Dilburig, Chenab Valley,
Koelz 9917; Kyelang, Koelz 538 (Pennell, 1943), Manimahesh, 3300 m; Rotang Pass, 3800
m, Lahaul Spiti Forest Division (Uniyal et al., 1982), Pangi valley; Birmor valley; Lahaul
valley; Dauladhar valley (Kapahi et al., 1993), Pangi; Bharmour; Lahaul; Kalpa; Dauladhar;
Barabhangal ranges  (Kapil, 1995), Rohtang slope, Lahaul-Spiti Aswal 6517 (Aswal and
Mehrotra, 1994), Rudranath Bugyal, Chamoli, Garhwal (Joshi, 1989), Satrundi, Chamba
(Rau, 1975); Uttar Pradesh: around Agora-Dodital, Uttarkashi district (Chandra and Pandey,
1983), Bhillangna Valley, Sahasru Tal, Tehri-Garhwal 5,300 m, Gupta RK 330 (Gupta, 1957,
1989), Buhna, Nar Parbat, Garhwal, 3000-4500 m, Rau MA 10271 (Rau, 1961, 1975),
Damdar Valley, Tehri-Garhwal 3700 m, Duthie 229 (Gupta, 1989), Dayara, Devkund 3300
m, Uniyal 3994 (Uniyal, 1968), Deodi Ramani, Garhwal, Anon 73386 (Gupta, 1989), Enroute
Rupkund, Garhwal, Bhattacharya and Mehrotra (Gupta, 1989), Gangotri, Tehri-Garhwal
2400-5000 m, Keshwanand 30 (Gupta, 1989), Harsil, Raithal, Sukhi, Sayara, Tehri-Garhwal
3000 m in Bhagirathi Valley, Uniyal 3994 (Gupta, 1989), Jumnotri, Tehri-Garhwal (Rau,
1963, 1975), on the way to Yumnotri, Tehri-Garhwal 2500-3500 m, Rau MA (Gupta, 1989),
Kedar Konta, east of Sutlej gorge (Royle, 1835-1940b), Kedar Nath; Herker Dun; Ponwali;
Tali; Harsil, Garhwal Himalaya 3000-4000 m (Uniyal, 1989), Kedarkanta, Tehri-Garhwal
4300 m, Drummond 22760 (Gupta, 1989), Kedarnath, Har-ki-dun, Ponwati, Tali, Harshil and
Gangotri in Garhwal Hills  (Kapil, 1995), Khaljhuni, Garhwal 2200-2500 m, cultivated (Rao
and Saxena, 1994), Kidarnath, Garhwal; Gangotri, Garhwal; Kumaon hills (Kapahi et al.,
1993), Kumaon, alpine regions (Rawat and Pangtey, 1987), Kumaon and Garhwal, alpine
regions (Joshi et al., 1995), Madhari Pass, Kumaun Strachey & Winterbottom (Duthie, 1906,
Pennell, 1943), Milam, Kumaun Schlagintweit 9647 (Pennell, 1943), Milam, Pindari,
Kumaon (Rau, 1975), Narparbat, Garhwal, 3000 m Rau MA 10271, 10506, Falconer 778
(Gupta, 1989), Pithoragarh District of Kumaon Hills (Kapil, 1995), Ponwali, Tehri-Garhwal
3300-3600 m, Uniyal 1667, 3843 (Gupta, 1989), Rupkund, Garhwal (Bhattacharyya, 1984),
Tungnath, Garhwal, 3600 m (Nautiyal, 1988), Tungnath, Garhwal, 3300 m, Kala and Gaur
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200 (Gupta, 1989), Valley of Flowers, Glacial Valley, Garhwal, 3800-4200 m, Malhotra BM
4601, 4645 (Gupta, 1989).
2. Neopicrorhiza scrophulariiflora Hong, Opera Bot. 75: 56. 1984 – Picrorhiza kurrooa
auct. non Royle: Hook. Fl. Brit. Ind. 4: 290. 1885; Picrorhiza auct. non Royle: Pennell,
Monogr. Acad. Nat. Sci. Philad. 5: 65. 1943 (as ‘scrophulariaeflora’).
Distribution: Eastern Himalaya to mountains of Yunnan, 4300-5200 m (Pennell, 1943),
Uttar Pradesh to Southwest China, 3600-4800 m (Polunin and Stainton, 1990). Uttar
Pradesh: Munsiari tehsil, Pithoragarh District, Kumaon (Malhotra and Balodi, 1984),
Pithoragarh District, Garhwal (Balodi, 1995), Thungnath, Uttarakhand, Garhwal, 3600 m,
cultivated, Smit 9602; Nepal: Bagmati zone, Rasuwa district, Langtang (Suwal, 1993),
Central Nepal (Bhattarai, 1993), Gorkha district, Central Nepal Olsen 303 (Olsen, 1998),
Gosaikunda (lake Gosainkund, lo: 08524E, la: 2802N), Langtang 4270 m Kanai & Malla
16257 (Malla, 1976), Jaljale Himal, East Nepal: Jaljale–Tin Pokhari, 4030-4130 m,
TI9110180; around Banduke, 4150 m, TI9110217 (Ohba and Akiyama, 1992), Jumla district,
Karnali, Western Nepal (Manandhar, 1986), Laurivinayak, Langtang 3900 m Malla 9246
(Malla et al., 1976), Murkhagari, Gorkha, Central Nepal, 4000 m, cultivated, Smit 9601C,
Thaple Himal, 4700 m (Kihara, 1955), West Nepal: PSW 4215; Central Nepal: SSW 1190;
East Nepal: Williams 309; TI720508, 3500-4800 m (Hara et al., 1982); Sikkim: Naku Chhu,
Smith & Cave 1965* (Pennell, 1943), North Sikkim; East Sikkim* (Kapahi et al., 1993),
Zemu valley, Llonakh, 13,000-16,000 ft, Smith 1343, Smith 1965, Smith 2251* (Smith and
Cave, 1911; P. scrophulariiflora Pennell, 1943), Choktsering Chhu, north of Jongri, 4000-
4200 m (Hara, 1966), Gamothang (Gopethang), 3800 m (Hara, 1966), Jongri (Dzongri), 4000
m (Hara, 1963), Jongri–Olothang (Onglakthang), 3900 m (Hara, 1966), Preig Chu–Jongri
(Prek Chhu), 2200-4000 m (Hara, 1966); Bhutan: Bhutan, 1971 Ramesh bedi 87, 121* (Bedi,
1971).
Distribution of both species is restricted to the Himalayan region and China. While P.
kurrooa occurs mainly in the Western Himalaya at an altitude of 3000-4300 meters, P.
scrophulariiflora is found mainly in the Eastern Himalaya at an altitude of 4300-5200 meters
(Pennell, 1943). These findings are confirmed by most of the botanical references, which
describe the occurrence of Picrorhiza species, as listed above. Marked locations (*) indicate
inaccurate identification. The nomenclature of the collections by Smith and Cave has been
corrected by Pennell (1943), while Kapahi et al. (1993) have not made any distinction
between the two species (Kapahi, personal communication). Bedi (1971) does not include a
description of the plant, and probably unaware of the existence of P. scrophulariiflora, he
may have identified his material erroneously.
Taxonomic notes on Picrorhiza and Neopicrorhiza |  17
Figure 2. Distribution of Picrorhiza species in the Himalaya region: ▬  ▬ Picrorhiza
kurrooa Royle; ▬▬ Picrorhiza scrophulariiflora Pennell.
Fieldwork
The plant material that was used for the experiments described in this thesis was
purchased from Gorkha Ayurved Company, Gorkha, Nepal. To establish the identity of
Picrorhiza species in this area, we performed fieldwork into Gorkha District, at Murkhaghari
(Centre for Community Development and Research; alt. 4000 m). At this location, the
exclusive presence of P. scrophulariiflora was observed (1996). Other observations are in
agreement with the exclusive occurrence of P. scrophulariiflora in Gorkha District, Central
Nepal (Olsen, 1998). Additional fieldwork was carried out at Thungnath, Garhwal in Uttar
Pradesh, India (G.B. Pant Institute of Himalayan Environment and Development; alt. 4000
m). At this location, the presence of P. scrophulariiflora was observed, as identified based on
the inflorescence (1996).
Except for fresh samples, market samples were obtained from different origin. Because
the suppliers were generally unaware of the proper scientific names, they were asked for the
origin of the material, and this information was used to establish a preliminary identity (table
1). Microscopical analysis of the material obtained from the market could not discriminate
between the two species.
All identifications were done by H.F. Smit, Department of Medicinal Chemistry,
Universiteit Utrecht, The Netherlands. Herbarium specimens are deposited at the National
Herbarium of The Netherlands, Utrecht University Branch (U).
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Table 1.  Market samples obtained during fieldwork or by mail order.
Supplier Acquired Origin Proposed identity
Ratna Enterprises, Colombo,
Sri Lanka
1995 South India, Nepala P. scrophulariiflora
Nardevi, Kathmandu, Nepal Aug. 1996 Nepal P. scrophulariiflora
Laurabir, Varanasi, UP, India Sept. 1996 Nepal P. scrophulariiflora
Arya Vastu Bhandar, Dehra
Dun, Garhwal, UP, India
Oct. 1996 Garhwalb P. kurrooa
Arya Vastu Bhandar, Dehra
Dun, Garhwal, UP, India
Spring 1997 Garhwalb P. kurrooa
Jammu, JK, India Nov. 1998 Himachal Pradesh P. scrophulariiflora
Hwa To Centre, Utrecht,
Netherlands
July 1999 China, Nepalc P. scrophulariiflora
a According to the supplier, the material is obtained from South India, and probably originates
from Nepal; b According to the supplier, the material originates from Garhwal, and is P.
kurrooa; c Olsen (1998), in describing the trade of medicinal plants from Gorkha, notices that
for several years, China purchased all Picrorhiza stocks from the Delhi market, being mostly
Picrorhiza from Nepali origin. Therefore, the material probably belongs to P.
scrophulariiflora.
Conclusion
In the present chapter, we described taxonomic aspects of the closely related species
Picrorhiza kurrooa and P. scrophulariiflora. Because the plant material that was used for the
experiments described in this thesis was obtained as simplex, and as there are no
discriminative features between the rhizomes of both species, the plant material could not
directly be identified. However, an inventory of the geographical distribution of both
Picrorhiza species provided sufficient circumstantial evidence to establish its proper identity.
The material was obtained from Gorkha Ayurved Company, Gorkha, Nepal, and originated
from Gorkha District. Literature review revealed that the distribution of P. kurrooa is
restricted to the Western Himalaya, from Kashmir to Kumaon, while P. scrophulariiflora is
found in the Eastern Himalaya, from Garhwal to Sikkim. This observation is a strong
argument to consider the identity of the Gorkha material to be P. scrophulariiflora.
Observations by Olsen (1998) confirm the exclusive occurrence of P. scrophulariiflora in
Gorkha District of Central Nepal. Fieldwork into Gorkha District at Murkhaghari (4000
meter) supports this conclusion, showing only the presence of P. scrophulariiflora in this
area. In flowering season, both species can readily be distinguished, on basis of the
remarkable differences in the inflorescence.
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Introduction
Most of the publications on the biological activities and constituents of Picrorhiza deal
with the species P. kurrooa, while P. scrophulariiflora is scarcely described. However, the
identification of the raw material has usually not been elaborated on in these publications.
Quite often, plant material is obtained through a chain of buyers and sellers, and ultimately
there is no information on the origin of the material. Generally, no distinction is made
between samples from Nepal (P. scrophulariiflora) and India (P. kurrooa). A proper
identification can only be made when selective criteria are found to distinguish between
rhizomes from both species, e.g. microscopically, chemically, or by DNA analysis.
However, these criteria have not been met so far. The difficulty in distinguishing both
species from each other based on rhizomes only makes interpretation of experimental results
on Picrorhiza species ambiguous. This uncertainty has to be taken into consideration when
referring to publications on P. kurrooa. In cases where the origin of the material in not clearly
described, there is a possibility that the material investigated is erroneously substituted for P.
scrophulariiflora. These observations provide ample arguments to introduce publications
on both species in this chapter.
4.1 Cucurbitacins
Introduction
The cucurbitacins constitute a group of triterpenic substances, especially known by
their bitterness and toxicity. They are characterized by the cucurbitane skeleton, are mainly
tetracyclic, and oxygenated at different sites. The basic structure is 9β-methyl-19-
norlanosta-5-ene (figure 1), also known as 10α-cucurbit-5-ene (Lavie and Glotter, 1971).
Cucurbitacins are usually present within plants as β-glucosides and have wide-ranging
pharmacological activities. Several authors have reviewed this group of compounds, from
a chemical (Lavie and Glotter, 1971), biological (Rehm, 1960, Guha and Sen, 1975), or

































Figure 1. Basic structure of the 10α-cucurbit-5-ene skeleton (9β-methyl-19-norlanosta-5-
ene)
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Cucurbitacins from Picrorhiza
So far, 23 different cucurbitacin glucosides and 1 aglucone have been isolated from
Picrorhiza species, mainly from P. kurrooa (table 1).
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† Constituent of P. kurrooa; ‡ constituent of P. scrophulariiflora.
Cytotoxicity
Strong cytotoxic effects have been described for several cucurbitacins, using KB cell
cultures, derived from human nasopharyngeal carcinoma, or HeLa cells (Miró, 1995). It
was suggested that the cytotoxic mechanism involves selective interference with DNA
synthesis, as seen by the inhibition of [3H]-thymidine incorporation in cultured
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lymphocytes incubated for 30 min with cucurbitacin B, D, or dihydrocucurbitacin B. RNA
and protein synthesis were not affected (Whitehouse and Doskotch, 1969). Later
experiments showed that cucurbitacin I inhibits the incorporation of radioactive precursors
into DNA, RNA, as well as protein in HeLa S3 cells. ID50 values of several cucurbitacins
were similar to the ED50 values of cucurbitacin-induced growth inhibition, suggesting a
relationship between inhibition of intracellular metabolic activity and growth-inhibitory
activity of cucurbitacins. Cell lysis due to exposure to cucurbitacins was excluded
(Witkowski et al., 1984).























































Cucurbitacins were also shown to inhibit the binding of cortisol to glucocorticoid
receptor (GCR) in HeLa cells at 37 °C in a dose-dependent manner. At 0-4 °C and in cell-
free HeLa systems, however, inhibition was decreased or completely abrogated, suggesting
a metabolic transformation of cucurbitacins in functionally HeLa cells into derivatives with
a higher affinity to GRC than the parent compounds. Moreover, the inhibition of cortisol
binding to GCR by cucurbitacins in intact cells at 37 °C showed a strong correlation with
cytotoxic activity, suggesting that cytotoxicity of cucurbitacins involves binding to the
glucocorticoid receptor (Witkowski and Konopa, 1981). Incorporation experiments
confirmed the suggestion of an active metabolite, because cucurbitacin I suppressed the
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incorporation of radio-labeled precursors when cells were permeabilized upon exposure,
but did not suppress incorporation when cells were exposed to cucurbitacin I after
permeabilization (Witkowski et al., 1984). Later experiments, however, have shown that
glucocorticoids alone do not affect the incorporation of radio-labeled precursors into HeLa
S3 cells and, in combination with cucurbitacin I, could not reverse its inhibitory activity,
while the concentrations of steroids used were large enough to induce complete inhibition.
These data suggest that the inhibition of macromolecule synthesis is not mediated by the
GCR, but instead might involve immediate extranuclear effects of glucocorticoids, which
are not necessarily receptor-mediated (Witkowski et al., 1984).
Effects on cytoskeleton
Cucurbitacins D, I, E, and 2-methoxy-cucurbitacin E were shown to induce
morphological changes to Ehrlich ascites tumor cells at low concentrations. Only at higher
concentrations, respiration, permeability, and viability of these cells were affected, without
an increase in morphological changes. Similar changes were observed in samples that were
taken 1 hour after i.p. injection of cucurbitacin D into ascites-bearing mice. In samples
taken 24 h after injection, however, no deformed or necrotized tumor cells were found
(Gitter et al., 1961). Furthermore, it was shown that lymphocytes of chronic lymphatic
leukemia patients as well as those of leukocytotic lymphosarcoma patients were much
more sensitive to cucurbitacin D (elatericin A) than those isolated from normal individuals
(Shohat et al., 1967). Exposure of prostrate carcinoma cells to cucurbitacin E also led to
the development of morphologically abnormal, multinucleated cells, which presented a
change in vimentin distribution. Furthermore, cucurbitacin E induced cell growth
inhibition of prostrate carcinoma cells, even after drug removal. It was shown to disrupt the
F-actin cytoskeleton, which correlated with antiproliferative effects (Duncan et al., 1996).
Moreover, cucurbitacin E was shown to interfere with the actin cytoskeleton of human
endothelial cells, preferentially targeting proliferating versus quiescent cells. It was
suggested that the condensation of actin microfilaments in quiescent cells, which does not
occur in proliferating cells, renders the molecular targets for cucurbitacin E unavailable for
interaction (Duncan and Duncan, 1997).
Antitumor activity
Cytotoxic and antiproliferative effects, as described above, make cucurbitacins
interesting agents in the treatment of tumors. The National Cancer Institute (NCI) has
screened several plants containing cucurbitacins and has isolated their active constituents
(Fuller et al., 1994). Cucurbitacins have shown in vivo inhibitory activity in several
carcinoma, sarcoma, and leukemia models (Gitter et al., 1961, Gallily et al., 1962,
Kupchan et al., 1967, Lavie and Glotter, 1971, Kupchan et al., 1972, Konopa et al., 1974,
Fang et al., 1984, Reddy et al., 1988).
Immunological and related activities
Cucurbitacin B, isolated from Ecballium elaterium (Cucurbitaceae), exhibited anti-
inflammatory activity in acetic acid-induced vascular permeability, serotinin-induced paw
edema, and bradykinin-induced paw edema in mice (Yesilada et al., 1988, 1989).
Furthermore, cucurbitacins B and E, isolated from Wilbrandia ebracteata (Cucurbitaceae),
showed anti-inflammatory activity in carrageenan-induced paw edema in rats (Peters et al.,
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1997), while cucurbitacin B reduced PGE2 levels in exudates of carrageenan-induced
pleurisy in mice (Peters et al., 1999). Cucurbitacin E, isolated from Conobea scoparioides
(Scrophulariaceae), and several related cucurbitacins were demonstrated to inhibit LFA-1-
and ICAM-1-mediated JY/HeLa cell adhesion. These results were in line with the
inhibition of actin polymerization in fMLP-stimulated neutrophils, suggesting that the
mechanism of inhibiting cell adhesion is by interference with the cytoskeleton (Musza et
al., 1994).
In addition to modulation of cell-mediated immunity, interference with humoral
immune responses has also been described. Picfeltarraenins, cucurbitacin glycosides
isolated from Picria fel-terrae (Scrophulariaceae), were shown to inhibit the classical and
alternative pathways of the complement system (Huang et al., 1998). Cucurbitacin I
showed only minor inhibition of the classical pathway (Knaus and Wagner, 1996).
In contrast to cucurbitacin B, cucurbitacin D was shown to enhance capillary
permeability. The activity was in a similar order of magnitude as that of histamine, while
the activity could not be reversed with antihistamines. The enhanced permeability was
associated with a persistent fall in blood pressure and the accumulation of fluid in thoracic
and abdominal cavities in mice. The long latent period before the appearance of
pharmacological effects, suggests that the compound had to be converted into an active
metabolite (Edery et al., 1961).
Adaptogenic activities
Cucurbitacin R-diglucoside was shown to moderately stimulate the secretion of
corticosterone by the adrenal cortex, and to inhibit stress- or ACTH-induced corticosterone
formation in vitro and in vivo, suggesting an adaptogenic effect. Furthermore, preliminary
administration of cucurbitacin R reversed stress-induced alterations in eicosanoid levels,
increasing PGE2 and decreasing 5-HETE, which supports the suggestion of adaptogenic
activity (Panossian et al., 1997, 1999). Cucurbitacin B, isolated from Ecballium elaterium,
was shown to have antihepatotoxic activities. It reduced CCl4-induced liver damage as
shown by a decrease in sGPT levels, hepatic collagen and β-lipoproteins, and a reduction
of pathological liver changes (Han et al., 1979, Miró, 1995, Agil et al., 1999).
In vivo toxicity
Due to severe toxicity, the medicinal usage of plants that produce high amounts of
cucurbitacins has become obsolete. LD50 values of several cucurbitacins are described in
literature, ranging from 0.5 mg/kg for cucurbitacin B (rabbits, i.v.) to 340 mg/kg for
cucurbitacin E (mice, p.o.) (David and Vallance, 1955, Edery et al., 1961, Le Men et al.,
1969). Particularly, the absence of ∆1, and the presence of ∆23 and 25-acetoxy functionalities
seem to enhance toxicity (Le Men et al., 1969).
4.2 Iridoid glucosides
Introduction
Iridoids represent a large group of monoterpenes and accumulate in a number of plant
families, mainly concentrated in the subclass Asteridae (Cronquist system). They consist of
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a basic cyclopentano-[c]-pyran skeleton, which is formed during ring closure of 8-epi-
iridodial (figure 2) and usually occur as glucosides. Several authors have reviewed their
occurrence (El-Nagar and Beal, 1980, Boros and Stermitz, 1990), distribution (Hegnauer
and Kooiman, 1978), biosynthesis (Inouye, 1978), and biological activities (Ghisalberti,


























Figure 2. Diagram of 8-epi-iridodial, precursor in the biosynthesis of catalpol.
Iridoids from Picrorhiza
Several iridoid glucosides have been isolated from Picrorhiza species (table 3).
Extensive research has been devoted to standardized iridoid fractions of P. kurrooa, e.g.
kutkin and Picroliv. Kutkin is obtained by crystallization and consists of the glucosides
picroside I and kutkoside in a ratio of 1: 2 and other minor glycosides (Singh and Rastogi,
1972, Ansari et al., 1988). Picroliv is a similar but less purified fraction, containing about
60 % of an equal mixture of picroside I and kutkoside (Dwivedi et al., 1989). More recent
publications describe Picroliv as a standardized iridoid fraction containing 60 % of this
mixture in a 1: 1.5 ratio (Dhawan, 1995).
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Table 3. Continued.
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† Constituent of P. kurrooa; ‡ constituent of P. scrophulariiflora.
Biological activities
A wide range of biological activities have been attributed to iridoids, such as
cardiovascular, antihepatotoxic, choleretic, hypoglycemic, hypolipidemic, anti-
inflammatory, antispasmodic, antitumor, antiviral, purgative, immunomodulatory,
antioxidant, anti-phosphodiesterase, neuritogenic, molluscicidal, and leishmanicidal
activities (reviewed by Ghisalberti, 1998).
In a number of publications referring to the antihepatotoxic, hepatoregenerative,
choleretic, and hypolipidemic effects of Picroliv, the preparation was shown to have
similar or more potent activities than silymarin, a purified fraction of Silybum marianum
(Asteraceae), commonly used in the treatment of liver disorders (reviewed by Dhawan,
1995). Hepatoregenerative effects were associated with an increased recovery of the liver
anti-oxidant system after partial hepatectomy or carbon tetrachloride-induced liver damage
of Picroliv-treated rats (Rastogi et al., 1995, 1997). Hypolipidemic effects were observed
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in rats with triton- and cholesterol-induced hyperlipidemia (Khanna et al., 1994). Oral
administration of Picroliv to mice prior immunized with sheep erythrocytes resulted in an
increase in hemagglutinating antibody titers, antibody-forming cells, and DTH responses to
sheep erythrocytes. Furthermore, it enhanced non-specific immune responses of peritoneal
macrophages and the [3H]-thymidine uptake by lymphocytes isolated from mice treated
with Picroliv (Puri et al., 1992).
Anti-inflammatory activity was observed for kutkin in experimentally induced
arthritis, edema, vascular permeability, and leukocyte migration in rodents (Singh et al.,
1993). Aucubin was also shown to potently inhibit phorbolester-induced edema in mice
ears, while catalpol and picroside II were not active (100 mg/kg, p.o.). The latter iridoids
showed only minor anti-inflammatory effects upon topical administration (Recio et al.,
1994). Moderate anti-inflammatory activity of picroside II, when administered topically,
was confirmed later, while pikuroside was ineffective (Jia et al., 1999). Picrosides II, III,
V, 6-feruloylcatalpol, and minecoside moderately inhibited chemiluminescence generated
by activated polymorphonuclear neutrophils (PMNs), while picroside I was not active;
scavenging effects of these compounds were excluded (Simons, 1989, p. 102). Picroliv
however, as well as picroside I, were shown to be moderate superoxide scavengers, while
kutkoside showed only weak activity (Chander et al., 1992). Furthermore, Picroliv
protected cells against hypoxia, enhanced the expression of VEGF and HIF-1, selectively
inhibited protein tyrosine kinase activity, and reduced PKC (Gaddipati et al., 1999).
4.3 Phenylethanoids
Only recently, another group of compounds have been isolated from Picrorhiza
species. P. scrophulariiflora was shown to constitute the phenylethanoid glucosides
scroside A-C and plantamajoside (Li et al., 1998). Plantamajoside, isolated from Plantago
major (Plantaginaceae), is a potent inhibitor of phosphodiesterase and 5-lipoxygenase
(Ravn et al., 1990), as is reported for similar compounds (Zhou et al., 1998). Moreover,
phenylethanoids were shown to be antibacterial (Didry et al., 1999) and scavengers of
reactive oxygen species (ROS; Çalis et al., 1999).
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‡ Constituent of P. scrophulariiflora.
4.4 Phenolics
Introduction
Monocyclic phenolic compounds are very common in the plant kingdom. They are
precursors and degradation products of lignin, which provides sturdiness to the plant and a
physical defense barrier against parasites (Steinegger and Hänsel, 1988, p. 366).
Furthermore, they usually act as antifungal agents, providing direct protection to the plant
(Kokubun and Harborne, 1995, Aoyama et al., 1997).
Phenolics from Picrorhiza
Vanillic acid, apocynin, and their respective glucosides have been isolated from
Picrorhiza (table 5).
Table 5. Phenolic compounds isolated from P. kurrooa and P. scrophulariiflora.
R = OH R = glucoseOHO
R
OMe vanillic acid
Rastogi et al., 1949†
picein
Stuppner and Wagner, 1989b†




Basu et al., 1971†
androsin
Stuppner and Wagner, 1989b†
Wang et al., 1993‡
† Constituent of P. kurrooa; ‡ constituent of P. scrophulariiflora.
Antioxidant activities
Apocynin, and to a minor extent vanillic acid, were isolated guided by their inhibition
of chemiluminescence by activated PMNs (Simons et al., 1989). Apocynin completely
inhibited oxygen uptake by activated neutrophils and human eosinophils, but not by human
alveolar macrophages. This effect was mediated by an inhibition of NADPH oxidase
activity, which was associated with the translocation of the cytosolic oxidase components
p47phox and p67phox to the membrane fraction of neutrophils (Simons et al., 1990, Stolk et
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al., 1994). In order to exhibit these effects, apocynin needs conversion into an active
metabolite by MPO and hydrogen peroxide, but so far, the structure of this compound has
not been elucidated (’t Hart and Simons, 1992, Stolk et al., 1994, Müller et al., 1999).
Furthermore, apocynin, upon prior activation, revealed inhibitory activity towards LTB4-,
fMLP-, and PAF-induced chemotaxis of PMNs, which was associated with an inhibition of
cytoskeletal rearrangement after stimulation with fMLP (Müller et al., 1999). Another
oxygen-related effect was discovered in the form of enhanced intracellular GSH synthesis,
which appeared to be mediated by increased expression of γ-GCS mRNA and enzyme
activity through activation of transcription factor AP-1 (Lapperre et al., 1999). These
effects have led to the testing of apocynin in several experimental models pertaining to a
wide range of diseases, especially those in which NADPH oxidase plays a role.
Anti-inflammatory activity
Apocynin reduced joint swelling in collagen-induced arthritis in rats (’t Hart et al.,
1990). Furthermore, it reversed the inhibition of cartilage matrix proteoglycan synthesis
induced by mononuclear cells isolated from rheumatoid arthritis (RA) patients. These
effects were accompanied by a reduced production of pro-inflammatory cytokines from
monocytes and T cells, without affecting T-cell proliferation. Moreover, apocynin
diminished the release of proteoglycan from cartilage matrix (Lafeber et al., 1999).
Continuous administration of apocynin prevented the formation of ulcerative skin lesions
induced by complete Freund’s adjuvant, without affecting humoral and cellular immune
responses, as determined by serum antibodies and DTH responses (’t Hart et al., 1992).
Moreover, apocynin concentration-dependently inhibited TXA2 formation, which effect
was associated with an inhibition of arachidonic acid-induced aggregation of bovine
platelets, whereas the release of PGE2 and PGF2α was stimulated (Engels et al., 1992, Lin
et al., 1999).
Other activities
In relation to the inhibitory effects of apocynin on NADPH oxidase activity,
implications for several diseases have been investigated. It has been shown to be effective
in mechanisms underlying, among others, sepsis (Wang et al., 1994, Mattson et al., 1996),
atherosclerosis (Aviram et al., 1996, Holland et al., 1997, 1998, Chen et al., 1998), and
asthma (Zhou and Lai, 1994, Tsukagoshi et al., 1994, 1995, Iwamae et al., 1998).
Apocynin did not demonstrate genotoxic effects, as determined by the Ames test and the
sister chromatid exchange assay (Pfuhler et al., 1995).
Conclusion
Picrorhiza species accumulate cucurbitacin glucosides, iridoid glucosides,
phenylethanoid glucosides, and acetophenone glucosides. These compounds have a wide
range of biological activities. Although hardly any information on the effects of the
cucurbitacins from Picrorhiza is available, it seems reasonable that they exhibit effects
similar to other cucurbitacins. In chapters 8 and 9, we confirm that some of the activities
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described here specifically relate to particular cucurbitacins isolated from Picrorhiza as
well.
Regarding the activities described for constituents of Picrorhiza, anti-inflammatory
effects seem to prevail. As far as iridoid glucosides are concerned, the effects described
mainly relate to a protection of the liver against damage and subsequent inflammation. In
contrast, phenylethanoid glucosides exhibit anti-inflammatory effects by inhibiting pro-
inflammatory responses, e.g. by diminishing phosphodiesterase and 5-lipoxygenase
activities. Acetophenones like apocynin contribute to the anti-inflammatory effects by
interfering with the formation of reactive oxygen species and enhancing the physiological
antioxidant system, which lead to a wide range of secondary effects.
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5.1 Introduction to relevant inflammatory processes
Introduction
As described in chapter 3, Picrorhiza species have been used extensively for centuries
in the traditional medicine of India for the treatment of various immune-related diseases. The
previous chapter gave an overview of the literature published on immunomodulatory
activity of constituents from Picrorhiza species. The current chapter describes
immunomodulatory activity of P. scrophulariiflora Soxhlet extracts. To evaluate this
activity, a series of in-vitro bioassays was performed as a reflection of nonspecific humoral
(complement) and cellular (neutrophil leukocytes) defense mechanisms, and specific
immune responses (T-cell activation). This section provides a background on several
inflammatory processes that are relevant to the assays described.
The complement system
The complement system provides an important nonspecific defense mechanism, which
involves a multitude of immune responses. Its primary goal is to recognize and eliminate
potentially harmful exogenous and endogenous structures from the human body. The
complement cascade is activated by complexes of antigens and their corresponding
antibodies, which activate the classical pathway (CP), or by a variety of other initiators, as
microbes or microbe- or plant-derived polysaccharides (zymosan, LPS, or inulin), which
induce the lectin pathway (figure 1).
The classical activation pathway involves the complement components C1, C4, and
C2, whereas the lectin pathway utilizes mannose-binding lectin (MBL) instead of C1, and
further uses C4 and C2 as well. As stipulated, C1 binds to antigen-bound IgM or IgG
antibodies, whereas MBL binds to sugar residues on their substrates, with as most
prominent specificities mannose, N-acetylglucosamine, and fucose. Activated C1 and
MBL-associated serine protease (MASP) lead to the formation of a surface-bound C4/C2
convertase, which converts C4 and C2 into a C3 convertase (C4bC2a), which is surface-
bound as well. This enzyme splits the most important complement component, C3, into
C3b and C3a. Subsequently, the alternative pathway, which provides a kind of
amplification loop, becomes activated by binding factor B to surface-bound C3b. The
resulting complex is activated by factor D, which is present in serum, producing the
alternative pathway C3 convertase (C3bBb). Binding of another C3b molecule to this
complex results in the formation of a C5 convertase (C3bBbC3b). Likewise, the classical
and lectin pathway generate another C5 convertase (C4bBbC3b). Both enzymes give rise to
the cleavage of C5 into C5b and C5a. Together with C6 and C7, C5b forms a lipophilic
complex, which intrudes the bilayers of cells. In concert with C8, a C9 polymerase is
formed which generates amphiphilic cylinders of about 13 C9 molecules. This complex
(membrane-attack complex, MAC) destabilizes the membrane and causes cell death
through lysis of the cell (Liszewski and Atkinson, 1993, Law and Reid, 1995, Matsushita
and Fujita, 1996).
The smaller subunits, which are deposited into plasma, act as granulocyte attractants
(C3a and C5a), anaphylatoxins (histamine releasers; C3a and C4a), or as kinins (C2b).
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They ultimately lead to a vast array of immune responses, such as the migration and
degranulation of granulocytes, contraction of smooth-muscle cells, increased vascular
permeability, and vasodilatation, which are instrumental in eliminating the harmful factor
(Frank and Fries, 1991, Law and Reid, 1995).
Figure 1. The activation steps of the complement system. Light shaded components
indicate enzymatic activity, dark shaded components are subunits, released in plasma.
Bold components are bound to cell-surfaces.
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Because of its potent pro-inflammatory and destructive capabilities, the complement
system is provided with a very extensive regulatory system (Liszewski et al., 1996). If
complement activation is not adequately controlled, it might cause tissue damage. Sublytic
amounts of MACs were shown to induce non-lethal stimulatory effects in synovial cells,
inducing the production of reactive-oxygen species and arachidonic-acid metabolites, the
release of IL-6, and increased expression of collagenase mRNA (Daniels et al., 1990, Jahn
et al., 1993). Furthermore, C3 metabolites and C9 were detected in synovia of patients with
acute arthritides and rheumatoid arthritis (RA), suggesting that the complement system is
involved in acute-transient inflammatory reactions in the arthritic joints. Normally,
complement-inhibiting proteins are present that protect against complement-mediated
tissue damage. However, the expression of the cell-associated complement inhibitor
protectin (CD59) was not seen in synovia of RA patients, making them targets for MAC-
mediated effects (Konttinen et al., 1996). In such cases, it would be vital to enhance the
regulation of complement activation in order to diminish tissue damage during flare-ups of
synovitis.
Polymorphonuclear leukocytes (PMNs)
A further role of complement proteins is opsonization of antigens, allowing them to
bind to receptors on PMNs. This causes activation of these neutrophils, ultimately leading
to a respiratory burst and degranulation of these cells. The products of this activation
process consist of reactive oxygen species, peroxidases, proteinases, proteases, hydrolases,
cytokines, and several other activator proteins (Root and Cohen, 1981, Cassatella, 1995).
These mediators of inflammation activate other immune cells, such as lymphocytes and
monocytes, or directly target the potentially pathogenic substance to the liver in order to
eliminate it from the body. However, due to lack of control of these processes, as is the
case in autoimmune diseases, such an immune response leads to a massive local and
ultimately systemic inflammation. Tissues may be damaged, mutilated, and destroyed,
releasing even more mediators that sustain the inflammation and lead to degenerative
chronic diseases, like rheumatoid arthritis (Bird, 1989).
T lymphocytes
In a later stage of the disease, T lymphocytes take over the leading role in the
inflammatory process. T cells are key players in cell-mediated immunity. In order to
generate an effective immune response, activation and subsequent expansion of antigen-
specific lymphocytes is required. Activation of T cells initiates when T-cell receptors
(TCRs) bind to specific antigens, in association with major histocompatibility complex
(MHC) molecules on the membrane of antigen presenting cells (APC). Several other
proteins and receptors are associated with the TCR and play a cooperative role in a
controlled manner of signal transduction (Abraham et al., 1992, Chambers and Allison,
1997, 1999). A persistent stimulatory signal ultimately leads to expansion and
differentiation of the specific T cells, under the influence of an array of cytokines and
growth factors (Swain, 1999).
Immunomodulatory activity of Picrorhiza scrophulariiflora |  67
Proliferation versus apoptosis
Activation of T-cells induces signal transduction pathways that lead to the release of
IL-2 and the expression of IL-2 receptor (IL-2R) during the transformation of T-cells from
the G0 to the G1 phase (Swain, 1999). The autocrine interaction of IL-2 with its receptor
induces T-cell progression from the G1 to the S phase, ultimately leading to proliferation
(Cantrell and Smith, 1984, Stern and Smith, 1986). In normal situations, cell proliferation
and cell death are balanced, leading to homeostasis. Several autoimmune diseases,
however, are associated with an increased survival of potential autoreactive T lymphocytes.
Cell accumulation can result from either increased proliferation or the failure of cells to
undergo apoptosis in response to appropriate stimuli (Thompson, 1995). In contrast to
necrotic cell death, apoptosis follows a specific pattern of membrane rearrangement,
cytoplasmic and nuclear condensation, and DNA cleavage. This process leads to the
formation of encapsulated cellular fragments, which are ingested by surrounding
phagocytes, without leading to a massive immune response, as is the case in cell necrosis
(Kerr et al., 1972, Savill et al., 1993).
Rheumatoid arthritis
Activated T lymphocytes that are differentiated into pro-inflammatory effector cells
release cytokines, which further induce cell-mediated immune responses (Swain, 1999).
They have been implicated as important mediators in inflammation and in the pathogenesis
of autoimmune diseases such as rheumatoid arthritis (Maini et al., 1995, Perkins, 1998).
Within the articular synovium, they activate synovial macrophages that produce a range of
pro-inflammatory cytokines such as IL-1β, TNFα, IL-6, and IL-15. These cytokines, which
are abundantly present in articular synovium, induce proliferation of synoviocytes,
enhancing local inflammatory processes. These affect lymphocytes, chondrocytes,
fibroblasts, and osteoclasts, inducing damage of bone, cartilage, and other connective tissue
components (Feldmann et al., 1996, Vaishnaw, et al., 1997, Starkebaum, 1998).
Furthermore, T cells that predominantly belong to the CD4+ subpopulation show
partial cross-reacting with stress protein, including heat-shock protein 60. Since similar
proteins are generated by bacteria, but also the human body, the inflammatory response is
at first instance heteroimmune, and later on predominantly autoimmune.
Therapeutic measures of RA often focus on immunomodulatory activity, by means of
nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or disease-modifying
antirheumatic drugs (DMARDs; ACR, 1996a). While NSAIDs only afford symptomatic
relief, without altering the course of the disease or preventing joint damage,
glucocorticoids and DMARDs interfere with the release of pro-inflammatory cytokines
(e.g. TNFα, IL-1, IL-2). As such, they have the potential to reduce and prevent joint
damage and to preserve joint integrity and function (Shevach, 1995, Cronstein, 1996). A
major disadvantage of these drugs, however, is their toxicity, which is usually proportional
to their efficacy (ACR, 1996b, Jackson and Williams, 1998). These side effects imply an
ongoing search for lead compounds that are able to selectively interfere with the
pathological processes underlying chronic inflammation.
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5.2 Immunomodulation in vitro
Introduction
Hence, our search for compounds that interfere with the activation of complement, the
release of chemiluminescence by neutrophil leukocytes, and the proliferation of T




Human pooled serum (HPS) was obtained from healthy volunteers (Bloedbank
Midden-Nederland, Utrecht, Netherlands), veronal buffers, and antigen-coated sheep and
rabbit erythrocytes were prepared according to Klerx et al. (1983). Veronal-buffered saline
(VBS0) contained 5 mM veronal and 150 mM sodium chloride in bidistilled water,
adjusted to pH 7.35. VBS0 with additional 0.15 mM Ca2+ and 0.5 mM Mg2+ is referred to
as VBS2+, whereas VBS0 containing 2.5 mM Mg2+ and 0.8 mM EGTA is called EGTA-
VBS. Erythrocytes were obtained from arterial blood supplied by Charles River (Someren,
Netherlands) and were washed thrice before use. Sheep erythrocytes were sensitized by
incubation with 1/800 diluted amboceptor (IgG antibody; Behring Diagnostics, Marburg,
Germany) for 10 min, washed, and resuspended in VBS2+ (4⋅108 cells/ml). Rabbit
erythrocytes were suspended in EGTA-VBS (3⋅108 cells/ml).
A suspension of serum-treated cell walls of Saccharomyces cerevisiae (zymosan) was
prepared by incubation of zymosan (Sigma Chemicals, St. Louis, MO, USA) with HPS at
37 °C for 30 min and subsequent washing and suspension in Hank’s balanced salt solution
(HBSS; Gibco BRL, Life Technologies, Pailsey, Scotland).
Phythaemagglutinin (PHA) was obtained from Difco (Detroit, MI, USA); RPMI 1640
medium and fetal calf serum (FCS) from Gibco BRL and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) from Sigma Chemicals. Sodium dodecyl sulphate
(SDS) solution (ICN Biomedicals, Aurora, Ohio, USA) was prepared by dissolving 20 g
SDS in a mixture of 50 ml distilled water and 50 ml dimethyl formide and adjusting the pH
to 4.7 with 80 % (v/v) acetic acid.
Plant material
Dried rhizomes of P. scrophulariiflora were purchased from Gorkha Ayurved
Company (Gorkha, Nepal). These samples had been collected in the Gorkha District. Olsen
(1998) described the exclusive occurrence of P. scrophulariiflora Pennell in this area.
Fieldwork confirmed the presence of P. scrophulariiflora in Gorkha District, at an altitude
of 4000 meter onwards, as identified by H.F. Smit, Department of Pharmacy, Universiteit
Utrecht, The Netherlands (Smit 9601), and described in chapter 2. Herbarium specimens
are deposited at the National Herbarium of The Netherlands, Utrecht University Branch
(U).
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Extraction procedure
Five hundred grams of powdered rhizomes were subjected to sequential Soxhlet
extraction, using light petroleum, diethyl ether, ethyl acetate, and methanol as extraction
fluids, respectively. The residual plant material was extracted with water under reflux for 2
hours. Organic solvents were removed under reduced pressure, the residue was mixed with
water to get a homogenous suspension, and all aqueous samples were lyophilized. The
extracts yielded 1 %, 2 %, 6 %, 17 %, and 10 % (w/w), respectively.
Analytical method
HPLC separation was performed on a modular Gilson system (dual 306 pumps, 234
auto injector, 170 diode array detector) provided with UniPoint software (v. 1.65) for
automated sample handling, and an Alltech Alltima C18 column (5 µm, 250 x 4.6 mm),
using a gradient of water and acetonitrile (0-5 min: 90 %; 5-10 min: 90 % → 80 %; 10-25
min: 80 %; 25-40 min: 80 % → 20 %).
Complement assays
Inhibitory activities of the extracts towards the classical (CP) and the alternative (AP)
pathways of the complement system were determined by a modified hemolytic microassay
(Klerx et al., 1983). In 96-wells round-bottom microtiter plates, HPS or heat-inactivated
serum as a control (CP: 50 µl; AP: 25 µl) was pre-incubated for half an hour at 37 °C with
an appropriate dilution series of the extracts in buffer (CP: VSB2+; AP: EGTA-VB).
Subsequently, erythrocytes (CP: 50 µl antibody-coated sheep erythrocytes; AP: 25 µl rabbit
erythrocytes) were added and the plates were incubated for one hour at 37 °C. Finally, the
plates were centrifuged (5 min, 2500 rpm), and 50 µls of the supernatants were mixed with
200 µl water per well in flat-bottom microtiter plates. The amount of hemoglobin released
was measured at 405 nm by means of an ELISA reader (SLT Labinstruments). Controls
consisted of erythrocytes incubated with water (100 % hemolysis) or buffer (0 %
hemolysis).
Chemiluminescence assay
Polymorphonuclear leukocytes (PMNs) were prepared from buffycoat residues, kindly
provided by the Bloedbank Midden-Nederland (Utrecht, The Netherlands), after
centrifugation in Ficoll-Hypaque, according to manufacturer’s instructions (Amersham
Pharmacia, Uppsala, Sweden). Cells were diluted to 1×107 PMNs/ml HBSS and dispensed
in white 96-wells flat-bottom microtiter plates in 50-µl amounts. Subsequently, 50 µl of an
appropriate dilution range of extract and 50 µl luminol (0.1 mM) were added to each well.
The cells were activated with 50 µl serum-treated zymosan (0.8 mg/ml) after which the
luminescence of each well was monitored every 2 min during a 30-min period, in a Titertek
Luminoscan luminometer (TechGen International). Maximum peak levels were used to
calculate the inhibitory activity of extracts compared with a control. Controls consisted of
cells with luminol and buffer.
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T-cell proliferation assay
Peripheral blood mononuclear cells (PBMC) were prepared from buffycoat residues
(Bloedbank Midden-Nederland) using Ficoll-Hypaque centrifugation, according to
manufacturer’s instructions (Amersham Pharmacia). Under sterile conditions, the cells were
diluted to 2×106 cells/ml RPMI 1640 (supplemented with 10 % FCS) and dispensed in 96-
wells microtiter plates (50 µl/well). Proliferation of cells was induced by 50 µl PHA (0.1
mg/ml), and 50 µl test samples were added in appropriate dilution ranges. After 4-day
incubation at 37 °C, T-cell proliferation was determined using a modified colorimetric MTT
assay (Hansen et al., 1989). To each well, 25 µl MTT (1 mg/ml) was added and the plate
was incubated for 4 hours at 37 °C. The formazan product formed was dissolved by adding
50 µl SDS-solution and by shaking for 1 h on a microtiter plate shaker. Absorbance values
were measured by an ELISA reader (SLT Labinstruments) operating at 550 nm. Controls




Strong inhibitory activity of P. scrophulariiflora towards the classical pathway of
complement was observed for the diethyl ether extract (IC50 = 1.9 ± 0.3 µg/ml). The
aqueous, light petroleum, methanol, and ethyl acetate extracts showed only moderate
activity, with IC50 values of 13 ± 2 µg/ml, 17 ± 5 µg/ml, 38 ± 5 µg/ml, and 55 ± 9 µg/ml
respectively (figure 2). None of the extracts tested inhibited the alternative pathway of


































Figure 2. Inhibitory activity of Picrorhiza Soxhlet extracts on the classical pathway of the
complement system. Data are expressed as means ± SEM of at least six experiments.
Chemiluminescence
Moderate inhibitory activity against chemiluminescence produced by activated PMNs
was observed for the diethyl ether (IC50 = 53 ± 5 µg/ml), ethyl acetate (IC50 = 50 ± 5
µg/ml), methanol (IC50 = 80 ± 2 µg/ml), and aqueous extracts (IC50 = 157 ± 34 µg/ml),
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respectively. Light petroleum extracts were inactive up to the highest concentration tested







































Figure 3. Inhibitory activity of Picrorhiza Soxhlet extracts on chemiluminescence of
activated neutrophils. Data are expressed as means ± SEM of at least six experiments.
T-cell proliferation
Activity against mitogen-induced proliferation of T lymphocytes was only seen for the
diethyl ether extract (IC50 = 13 ± 2 µg/ml), while the other extracts were inactive up to the














































Figure 4. Inhibitory activity of Picrorhiza Soxhlet extracts on T-cell proliferation. Data are
expressed as means ± SEM of at least six experiments.
5.3 Anti-inflammatory activity in vivo
Introduction
Carrageenan-induced paw edema is a well-known model for studying the activity of
anti-inflammatory agents. Although the mechanisms underlying this model are not fully
understood yet, several inflammatory processes have been suggested to play a role, e.g.:
activation of complement, release of reactive oxygen or nitrogen species by activated
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phagocytes, and the release of pro-inflammatory cytokines by monocytes (Di Rosa, 1972,
Hirschelmann and Bekemeier, 1981, Vinegar et al., 1987). Although these processes are
mainly described for carrageenan-induced paw edema in rats, they may also apply to
experimentally induced immune responses in mice.
Although no experimental animal model completely resembles the features of
rheumatoid arthritis in humans, collagen-induced arthritis (CIA) in mice mimics
considerably the processes that play a role here (Trentham, 1982). Several authors have
demonstrated the role of T cells in the development of CIA, by the isolation of collagen
type II (CII)-reactive T cells (Dallman and Fathman, 1985, Holmdahl et al., 1985), the
resistance to CIA of anti-CD4 treated mice (Ranges et al., 1985), and amelioration of CIA
by restricted TCR-specific antibodies (Moder et al., 1992, Osman et al., 1993).
Furthermore, the development and progression of CIA was inhibited by IL-10, which
suppresses Th1 cells and monocytes/macrophages (Tanaka et al. 1996, Walmsley et al.,
1996). Direct evidence demonstrated that, except for a cellular response, an additional
humoral factor is necessary in order to maintain an arthritic response (Seki et al., 1988).
Additional observations suggest an important role for IL-12 to enhance the cellular and
humoral anti-CII responses in DBA/1 mice (Szeliga et al., 1996). This is supported by the
observation that administration of CII along with Freund’s adjuvant supplemented with
Mycobacterium (CFA) is strongly enhancing the susceptibility to CIA (Courtenay et al.,
1980). Other predisposing factors that are required in order to induce CIA in mice are the
mouse strain: only mice with the MHC haplotype H-2q and with a certain Vα/β-TCR
repertoire are found susceptible to CIA (Wooley et al., 1981, Moder et al., 1992, Osman et
al., 1993); sex: female sex hormones suppress the development of CIA (Holmdahl et al.
1986); and age: highest susceptibility was found in mice ≥ 8 weeks of age (Wooley et al.,
1983). In addition, especially native bovine collagen type II was able to elicit an arthritic
response (Courtenay et al., 1980), and a booster immunization of CII enhanced the
susceptibility to CIA (Kato et al., 1996). These predisposing factors are all taken into




λ-Carrageenan was obtained from Fluka (Buchs, Switzerland), and sodium
carboxymethylcellulose (CMC), highly viscous, from Bufa (Uitgeest, The Netherlands).
Native bovine collagen type II from the metacarpal joint of the front paws was a kind gift
from the Department of Rheumatology, Nijmegen, Netherlands. Complete Freund’s
adjuvant (CFA) with Mycobacterium butyricum was obtained from Difco (Detroit, US).
Cucurbitacin E was obtained from Extrasynthese (Genay, France), dexamethasone and
prednisone from Bufa, and apocynin from Roth (Karlsruhe, Germany). Androsin was
obtained by glucosylation of apocynin using α-acetobromoglucose (Mauthner, 1918). Its
spectral data were found to be identical with those reported in literature (Junior, 1986).
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Animals
Specific-pathogen-free male BALB/c mice were obtained from the Central Animal
Laboratory (Utrecht, The Netherlands) and female DBA/1 mice from Bomholtgard (Rye,
Denmark). Both strains were maintained under standard housing conditions and provided
with food and water ad libitum. At the start of the experiments, the mice were 8-10 weeks
old.
Carrageenan-induced paw edema
For the determination of effects on acute inflammation, a carrageenan-induced paw
edema model was used. Male BALB/c mice (6 per group) were orally given extracts,
suspended in 0.5 % CMC, either in three consecutive daily doses or in a single dose, one
hour before the induction of paw edema. The control group was given dexamethasone (30
mg/kg p.o.) one hour before induction, while the blank groups received vehicle only, either
in three consecutive daily doses or in one dose. Inflammation was induced by subplantar
injection of a homogenous suspension of 1 % λ-carrageenan in physiological saline (25 µl).
Paw edema was measured in every mouse hourly during seven hours after induction with a
computerized micrometer device. Mean values of treated groups were compared with mean
values of a control group. The differences between the experimental groups and the control
group were statistically analyzed using the Student’s t-test.
Collagen-induced arthritis
To assess any effect on chronic inflammation, extracts were tested in a modified
collagen-induced arthritis model in mice (Joosten et al., 1996). A solution of CII in 0,05 M
acetic acid (2 mg/ml) was suspended in an equal volume of CFA solution containing 4
mg/ml Mycobacterium butyricum. At the start of the experiment, the mice were
conditioned to the handling procedures for one week to decrease stress. The mice were
immunized by injecting 100 µl FCA emulsified in CII solution intradermally at the tail base
under a mild anesthesia with ether. After three weeks, a booster injection of 200 µl (100
µg) CII in phosphate-buffered saline was given intraperitoneally. In the course of the next
three weeks, the clinical severity of arthritis was graded every other day, based on the
changes in swelling and redness of toes, foot pad, and ankle, with a maximum score of 2
per paw (table 1).
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Table 1. Scoring table of arthritis assessment.
symptoms score
swelling and redness of 1 toe 0.25
swelling and redness of at least 2 toes 0.50
swelling of foot pad 0.75
swelling and redness of toes and swollen foot pad 1.00
swelling and redness of toes and foot pad 1.25
swelling and redness of toes and minor swelling of foot pad and ankle 1.50
swelling and redness of toes and major swelling of foot pad and ankle 1.75
swelling and redness of toes, foot pad, and ankle 2.00
Two persons independently performed the scoring, and the mean cumulative value for
all paws was taken as the arthritic index (AI). Mice were considered to have arthritis when
AI was at least 1. Three endpoints were chosen for the evaluation of the experiment:
incidence of arthritis (only including mice with AI ≥ 1), day of onset of arthritis (AI ≥ 1),
and severity of arthritis (including all mice).
Extracts were suspended in 0.5 % CMC and given orally in one daily dose of 200
mg/kg for 36 consecutive days, starting on the day of immunization. Prednisone (3 mg/kg
p.o.) served as a positive control. Mean AI values of treated groups (n = 10) were
compared with mean values of the control group. The differences between the experimental




Treatment of mice with light petroleum, diethyl ether, ethyl acetate, methanol, or
aqueous extracts (500 mg/kg) of P. scrophulariiflora one hour before the induction of paw
edema did not inhibit paw swelling. The aqueous extract even enhanced the edema for
about 25 %, but this was only significant at t = 4 h. Treatment with dexamethasone (30
mg/kg p.o.) inhibited paw edema significantly from two hours after induction onward, with
a maximum effect (76 %) at t = 5 h (figure 5).
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Figure 5. Effects of single treatment with Picrorhiza extracts (500 mg/kg) and
dexamethasone (30 mg/kg) on carrageenan-induced paw edema (PE = light petroleum
extract, DE = diethyl ether extract, EA = ethyl acetate extract, Me = methanol extract, Aq
= aqueous extract, dex = dexamethasone). Data were expressed as means ± SEM (n = 6
per group) and statistically analyzed by the Student’s t-test. P-values are < 0.05 (*), <
0.01 (**), or < 0.001 (***).
Administration of 500 mg/kg/day diethyl ether extract for three days induced a
significant inhibition of paw edema from 3 hours after induction onward, with a maximum
effect (41 %) at t = 3 h. Other extracts were not active. Prednisone (3 doses of 5
mg/kg/day) inhibited paw edema for 51 % at t = 3 h, while a maximum effect (61 %) was
reached 5 hours after induction (figure 6).
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Figure 6. Effects of prolonged oral treatment with Picrorhiza extracts (500 mg/kg) and
single oral treatment of prednisone (5 mg/kg) on carrageenan-induced paw edema (PE =
light petroleum extract, DE = diethyl ether extract, EA = ethyl acetate extract, Me =
methanol extract, Aq = aqueous extract, pred = prednisone). Data were expressed as
means ± SEM (n = 6 per group) and statistically analyzed by the Student’s t-test. P-values
are < 0.05 (*), < 0.01 (**), or < 0.001 (***).
To assess whether the inhibitory effects of the diethyl ether extract were dose-
dependent, a second experiment was performed in which 500 and 1000 mg/kg/day,
respectively, were administered orally for three days. Based on pilot experiments, it was
assumed that three doses of 250 mg/kg did not significantly inhibit carrageenan-induced
paw edema. A significant inhibition of paw edema was observed upon administration of
500 and 1000 mg/kg/day, starting two hours or one hour after induction, respectively, up to
t = 6 h. A maximum effect was observed for 1000 mg/kg (64 %) at t = 3 h, and for 500
mg/kg (48 %) at t = 4 h (figure 7).
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Figure 7. Effect of prolonged treatment with diethyl ether Picrorhiza extract (DE; 1000
and 500 mg/kg p.o.) on carrageenan-induced paw edema. Data were expressed as means ±
SEM (n = 6 per group) and statistically analyzed by the Student’s t-test. P-values are <
0.05 (*), < 0.01 (**), or < 0.001 (***).
In addition, apocynin, an inhibitor of NADPH oxidase and responsible for several anti-
inflammatory effects (chapter 4), was tested to assess whether it was responsible for the
effects observed. Quantitative analysis was performed to determine the content of this
metabolite and its glucoside, androsin, in Soxhlet extracts of P. scrophulariiflora. HPLC
analysis revealed the presence of 1.4 % apocynin and 0.9 % androsin in the diethyl ether
extract (table 2). Therefore, apocynin was tested in three doses (1, 10, and 100 mg/kg),
given orally for three days before induction of paw edema. Measurement of paw swelling,
however, did not show any inhibitory effect by apocynin in this model (figure 8).
Table 2. Contents of apocynin and androsin in Soxhlet extracts of P. scrophulariiflora.
Extract Apocynin Androsin
light petroleum 0.35 ± 0.00 % nd
diethyl ether 1.4 ± 0.1 % 0.86 ± 0.26 %
ethyl acetate 1.0 ± 0.0 % 1.9 ± 0.01 %
methanol nd 0.47 ± 0.02 %
aqueous nd nd
nd = not detectable

















Figure 8. Effect of prolonged treatment with apocynin (100, 10, and 1 mg/kg p.o.) on
carrageenan-induced paw edema. Data were expressed as means ± SEM (n = 6 per group)
and statistically analyzed by the Student’s t-test.
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Collagen-induced arthritis
In addition to acute inflammation, we also examined the effects of extracts of P.
scrophulariiflora in a model of chronic inflammation. Preliminary experiments showed
that sub-chronic administration of high doses of plant material (1 g/kg) resulted in severe
gastro-intestinal symptoms (accumulation of undigested material in the stomach,
obstruction in intestine), while administration of the diethyl ether extract (200 mg/kg) for 6
weeks did not reveal these effects, as confirmed by toxicity studies (section 5.4). Ethyl
acetate and methanol extracts of P. scrophulariiflora (200 mg/kg) given from t = 0 onward
showed only a minor decrease, while diethyl ether extract significantly (χ2; P < 0.05)
inhibited the incidence of arthritis (AI ≥ 1). Furthermore, treatment with apocynin also
significantly inhibited incidence of arthritis (χ2; P < 0.01), while prednisone completely
inhibited development of collagen-induced arthritis (figure 9).



































Figure 9. Effects of oral treatments with Picrorhiza extracts (200 mg/kg), apocynin (20
mg/kg), or prednisone (3 mg/kg) on the incidence of arthritis (DE = diethyl ether extract,
EA = ethyl acetate extract, Me = methanol extract, apo = apocynin, pred = prednisone).
Data were expressed as percentages of animals with AI ≥ 1.
The mean arthritic scores of mice treated with Picrorhiza extracts or controls,
expressed as the arthritic index, did not differ significantly. Treatment with apocynin,
however, moderately diminished the severity of arthritis, although not significantly. The
mean arthritic index of mice treated with prednisone, however, remained zero throughout
the experiment. The day of onset of arthritis shifted from 27 to 29 days for the extracts and
to 31days for apocynin (figure 10).
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Figure 10. Effects of oral treatment with Picrorhiza extracts (200 mg/kg), apocynin (20
mg/kg), or prednisone (3 mg/kg) on the development of arthritis (DE = diethyl ether
extract, EA = ethyl acetate extract, Me = methanol extract, apo = apocynin, pred =
prednisone). Data were expressed as means ± SEM of all animals.
5.4 Exclusion of toxicity in vivo
Introduction
As indicated in section 5.3, in combination with carboxymethylcellulose (CMC),
higher doses of P. scrophulariiflora extracts incidentally gave rise to gastro-intestinal
obstructive reactions, sometimes leading to death of the animals. To exclude that these
toxic effects had to be ascribed to metabolites probably enriched in the form of extracts,
rather than to the whole plant product, or to a combination of extract with CMC, the
toxicity of extracts was tested in the absence of vehiculum.
Material and methods
Animals
Randomly bred Swiss mice, aged 8-12 weeks, were obtained from Harlan (Zeist, The
Netherlands). The mice were randomly divided in groups of 7, maintained under standard
housing conditions, and provided with food and water ad libitum throughout the
experiment.
Toxicity assay
Diethyl ether Soxhlet extract of P. scrophulariiflora (200 mg/kg) was administered by
gastrointestinal catheter three times a week (Mon., Wed., Fri.). After 3 weeks and 6 weeks,
respectively, mice were weighed, killed, and their thymus, spleen, liver, and mesenteric
lymph nodes were removed. All organs were weighed individually, except for the
mesenteric lymph nodes, which were weighed together. Means of the treated groups were
compared with means of a control group. The differences between the experimental groups
and a control group were statistically analyzed using the Student’s t-test.
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Results
Diethyl ether Soxhlet extract and ethanol reflux extract of P. scrophulariiflora were
administered orally thrice a week for 3 or 6 weeks. Although the weights of the spleen and
the liver were somewhat increased after administration of diethyl-ether extract for 6 weeks,
these differences were not statistically significant, as determined using the Students t-test
(figure 12B). Moreover, no significant differences were found in total weight or in weight
of thymus, spleen, liver, or mesenterial lymph nodes between mice treated with diethyl
ether extract (200 mg/kg p.o.) and blanks or between mice treated with ethanol extract (200
mg/kg p.o.) and blanks (figures 11 and 12).















Figure 11. Weights of mice after 3 or 6 weeks of treatment with diethyl ether Soxhlet
extract (DE) or ethanol reflux extract (Et) of P. scrophulariiflora. Data were expressed as
means ± SEM (n = 6-7 per group) and statistically analyzed by the Student’s t-test.
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igure 12. Weights of organs isolated from mice treated with diethyl ether Soxhlet extract
DE) or ethanol reflux extract (Et) of P. scrophulariiflora. A: After 3 weeks of treatment
ith DE extract. B: After 6 weeks of treatment with DE extract. C: After 3 weeks of
reatment with Et extract. D: After 6 weeks of treatment with Et extract. Data were
xpressed as means ± SEM (n = 6-7 per group) and statistically analyzed by the Student’s
-test.
iscussion
The diethyl ether Soxhlet extract of P. scrophulariiflora was the most anti-
nflammatory of all extracts prepared. The activity concerned both nonspecific
complement and respiratory burst) and specific (T-cell proliferation) immune responses.
urthermore, significant inhibition of acute inflammation in vivo was observed for this
xtract after prolonged treatment. The light petroleum and aqueous extracts were
oderately active in inhibiting the classical complement pathway, while the ethyl acetate
nd methanol extracts moderately inhibited chemiluminescence by activated PMNs. In
ivo, however, these extracts were completely inactive.
The inhibition of the classical complement pathway can be due to several effects.
ctive compounds in the extract can bind or alter particular components of the
omplement system, or inactivate converting enzymes, eliminating their involvement in the
ascade. Alternatively, certain compounds can activate the complement cascade, with as
esult a depletion of complement activity. Further research has to reveal the nature of the
ffects observed.
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The in vivo anti-inflammatory activity of the diethyl ether extract is in line with the
effects observed in vitro for this extract. Although not all mechanisms underlying
carrageenan-induced paw edema have been identified yet, it is a very useful model for the
screening of anti-inflammatory agents. In rats, the model has been used since 1962 for this
purpose (Winter et al., 1962). Regarding the possible mechanisms involved, several
inflammatory processes have been suggested to play a role, as e.g. activation of
complement, release of mediators by activated mast cells, release of kinins, the release of
reactive oxygen or nitrogen species by activated phagocytes, arachidonic acid metabolites,
and pro-inflammatory cytokines (Di Rosa, 1972, Hirschelmann and Bekemeier, 1981,
Vinegar et al., 1987). We assume that at least a part of these processes is subject of
inhibition by P. scrophulariiflora extracts.
Moderate inhibitory activity on activated neutrophils in vitro, as shown for the diethyl
ether and the ethyl-acetate extracts, may be ascribed to acetophenones. Similar effects have
been ascribed to P. kurrooa extracts, in which such an activity is mainly attributed to
apocynin (Simons, 1989). The presence of apocynin has been reported in P.
scrophulariiflora as well (Wang et al., 1993). The presence of apocynin was established by
HPLC in diethyl ether and ethyl acetate extracts, while androsin, its O-β-D-glucoside, was
identified in diethyl ether, ethyl acetate, and methanol extracts of P. scrophulariiflora.
However, androsin did not show any inhibitory effect on the respiratory burst of activated
neutrophils in vitro (data not shown). Therefore, apocynin may be largely responsible for
the moderate in vitro anti-oxidative activity of the diethyl ether and the ethyl acetate
extracts.
Furthermore was assessed whether apocynin was responsible for the anti-inflammatory
activity of the diethyl ether extract in the carrageenan-induced paw edema model. Although
androsin was not active in vitro, it may play a similar role as apocynin in vivo, because the
sugar moiety of O-β-D-glucosides is generally hydrolyzed by β-glucosidase, produced by
the intestinal flora, following oral administration (Rowland et al., 1986). The content of
apocynin and androsin in the diethyl ether extract was determined at 1.4 % and 0.9 %
(w/w), respectively. Therefore, apocynin was tested in three consecutive daily doses of 1,
10, or 100 mg/kg in carrageenan-induced paw edema. However, apocynin did not show any
anti-inflammatory effect in this model, suggesting that compounds other than apocynin are
responsible for the anti-inflammatory effects observed.
Collagen-induced arthritis (CIA) was used as a model to determine the effects of P.
scrophulariiflora extracts on chronic inflammation. Treatment with 200 mg/kg diethyl
ether extract significantly reduced the incidence of arthritis (AI ≥ 1), while ethyl acetate
and methanol extracts did not affect this parameter. However, neither extract affected the
severity of arthritis. In addition, the effect of apocynin (20 mg/kg p.o.) on the development
of CIA was assessed. Apocynin significantly reduced arthritis incidence, while it only
moderately decreased arthritis severity. These results are partially in line with the anti-
arthritic activity of apocynin in collagen-induced arthritis in rats, obtained when the
substance was added to the drinking water of rats (’t Hart et al., 1990). One possible
explanation for the discrepancy observed with our experiments is the short half-life of
apocynin, which might require continuous exposure of animals to apocynin in order to
maintain body concentrations that are sufficient to reach the desired effect. Moreover,
Immunomodulatory activity of Picrorhiza scrophulariiflora |  83
apocynin might interfere with processes in CIA in rats, which are of lower importance in
the mouse model. At least, our results suggest that the in-vitro inhibitory effects of the
diethyl ether extract on complement activation, chemiluminescence of activated PMNs,
and T-cell proliferation, are not sufficient to inhibit collagen-induced arthritis in mice. This
might be due to underdosage, low biological availability, an insufficient pharmacokinetic
profile, or to metabolic inactivation of active compounds in vivo. It is also possible that
pathological processes, other than those referred to and insufficiently inhibited by the
diethyl ether extract, lead to the development of collagen-induced arthritis in mice.
Because sub-chronic administration of powdered rhizomes of P. scrophulariiflora
resulted in severe gastro-intestinal symptoms, the toxicity of the active diethyl ether extract
and an ethanol reflux extract were determined. Administration of diethyl ether or ethanol
extract of P. scrophulariiflora for 3 and 6 weeks thrice a week to Swiss mice did not reveal
any significant toxicity involving body weigh and weights of critical lymphoid organs
including thymus, spleen, liver, and mesenterial lymph nodes.
In conclusion, of the extracts of P. scrophulariiflora tested, the diethyl ether extract
was the most effective in inhibiting the classical pathway of complement, the release of
reactive oxygen species by activated neutrophil leukocytes, and the mitogen-induced
proliferation of T lymphocytes. Furthermore, this extract exposed anti-inflammatory
activity in vivo, as demonstrated in an acute carrageenan-induced paw inflammation model.
This effect may be due to the presence of compounds, which inhibit activation of
complement. The contribution of compounds that interfere with the release of reactive
oxygen species by activated PMNs to the anti-inflammatory effect observed seems less
pronounced, since apocynin, a potent anti-oxidant and present in the diethyl ether extract,
was not effective in inhibiting carrageenan-induced paw edema. A combination of
immunomodulating compounds with different mechanisms of action might be necessary to
produce anti-inflammatory activity in vivo. Several known, but also as yet unidentified
immunomodulatory compounds may contribute to this activity. To this end, a search for
biological active compounds was undertaken by means of activity-guided isolation, as
described in chapters 6 and 7.
The in vivo effects were not associated with significant toxicity, as tested in mice by a
semi-chronic assay involving body weight and weights of critical lymphoid organs. Even in
doses up to 100 × the intended dose of application in humans, the extracts were devoid of
significant toxicity.
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6.1 Purification of the diethyl-ether extract
Introduction
As described in chapter 5, the effects of sequential Soxhlet extracts of P.
scrophulariiflora in the classical complement pathway were determined. The diethyl ether
extract showed the highest inhibitory activity, with an IC50 value of 1.9 µg/ml.
The complement system provides an important nonspecific defense mechanism, which
involves a multitude of immune responses. Its primary goal is to recognize and eliminate
potentially harmful exogenous and endogenous structures from the human body.
Furthermore, split products of complement activation (anaphylatoxins) accumulate in
plasma, and ultimately lead to a vast array of immune responses (Liszewski and Atkinson,
1993; chapter 5). If complement activation is not adequately controlled, it might cause
serious tissue damage. Deranged complement activation has been implicated in the
degeneration of synovial structures in rheumatoid arthritis patients (Konttinen et al., 1996).
In such cases, regulation of the complement activation should be enhanced in order to
diminish tissue damage during flare-ups of synovitis. In search for new compounds
inhibiting complement activation, the diethyl ether extract of P. scrophulariiflora was
subjected to activity-guided fractionation, based on its effect on the classical complement
pathway, leading to complement depletion.
Material and methods
Materials and analytical methods
Silica 60 and Silica LowBar columns were obtained from Merck (Darmstadt,
Germany) and Sephadex LH20 from Pharmacia (Uppsala, Sweden).
TLC analysis was carried out on precoated Si60 F254 Silica plates (Merck). Typically,
10-µl solutions were applied to the plate and dried. The plate was developed in a saturated
chamber with a mixture of ethyl acetate, methanol, and water in a ratio of 20: 3: 2, and
sprayed with a 1: 1 mixture of vanillin (1 % w/v in ethanol) and sulfuric acid (5 % v/v in
ethanol). Colored spots were detected after heating for 5 min at 110 °C.
HPLC separation was performed on a modular Gilson (Middleton, USA) system (dual
306 pumps, 234 auto injector, 170 diode array detector, FC 204 fraction collector)
provided with UniPoint software (v. 1.65) for automated sample handling, and an Alltech
Adsorbosphere Silica column (Deerfield, USA; 5 µm, 250 x 10 mm). Preparative HPLC
was performed using a gradient with cyclohexane and ethanol (0-2 min: 100 %; 2-10 min:
100 % → 93 %; 10-20 min: 93 %; 20-30 min: 93 % → 85 %).
Complement assay
The fractions were tested in the classical complement pathway, as described
previously in chapter 5.
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Silica column chromatography
Soxhlet extracts from the rhizomes of P. scrophulariiflora were obtained and tested in
the complement assay as described in chapter 5. The diethyl-ether extract (0.5 g) was
subjected to Silica column chromatography (50 cm × 2 cm diameter) using a diethyl ether:
ethyl acetate mixture in a ratio of 1: 1 as eluent. The column was eluted and 6 fractions of
5 ml and 4 fractions of 10 ml were collected. Pilot trials showed that further elution with
100 % ethyl acetate did not enhance the separation at this stage. Therefore, the remaining
material on the column was eluted with 500 ml dried methanol. The separation was
monitored with TLC and all fractions were tested in the complement assay.
Sephadex LH20 and preparative HPLC
A similar Silica column separation as described above was performed on the diethyl
ether extract (3 g) using a larger column (50 cm × 5 cm diameter) to obtain more material
(0.9 g methanol fraction). The methanol fraction (170 mg) was subjected to Sephadex
LH20 chromatography with methanol as eluent. Sixty fractions of 7 ml were collected,
analyzed with TLC, and tested on volume base in the complement assay. Fractions 19-37
were pooled (120 mg) and further purified with preparative HPLC (figure 4), as described
above. The separation was performed 7 times and corresponding fractions were pooled.
Ten fractions were collected, dried, and tested.
Results and discussion
Powdered rhizomes of P. scrophulariiflora were subjected to sequential Soxhlet
extraction by light petroleum and diethyl ether, respectively, as described in chapter 5. The
first step of the purification process of the diethyl ether extract consisted of a separation
with Silica column chromatography (figure 1).
The total yield of the fractions (117 %) exceeded the initial amount due to Silica,
which partly dissolved in the eluent. Fraction 10 showed the strongest inhibitory activity
(IC50 = 0.5 ± 0.0 µg/ml). Fractions 3 and 4 were similar in both TLC profile and activity
(IC50 = 2.4 ± 0.3 µg/ml and 3.1 ± 0.5 µg/ml, respectively), while other fractions were less
active (figure 2).
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Figure 2. Effects of Silica column chromatography fractions on the classical pathway of
complement activation. Data of fractions were expressed as means ± SEM of 2
measurements. Results were reproduced in 2 independent separation experiments.
A similar purification of the diethyl ether extract (3 g) as described above was
performed on a larger Silica column, yielding a methanol fraction with a similar TLC
profile and activity (IC50 = 1.6 ± 0.6 µg/ml; 30 % yield over one step) as the methanol
fraction of the previous separation. A part of this fraction (170 mg) was further separated
with Sephadex LH20 using methanol as eluent. Fractions 19-37, which showed highest
activity on volume base (figure 3), were pooled yielding 124 mg (73 % yield over one step;
IC50 = 0.9 ± 0.1 µg/ml). This fraction was further purified using preparative HPLC (figure
4), yielding 10 fractions, which were dried and tested (figure 5). Fractions 3 (8 % yield
over one step) and 4 (11 % yield over one step) showed highest activity (IC50 = 0.8 µg/ml
and 0.5 µg/ml, respectively). However, these fractions revealed at least five spots on TLC
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analysis, while HPLC separation did not enhance the purity. Further purification of the


















Figure 3. Volume-based inhibition of the classical route of complement activation by
















0 20 40 
Minutes 
 fraction 1 2 3 4 5 6 7 8 9 10 
Figure 4. Chromatogram with absorbance units (AU) at 220 nm obtained by preparative-
HPLC separation of active Sephadex LH20 fractions.
























Figure 5. Inhibition of the classical pathway of complement activation by preparative-
HPLC fractions, obtained by separation of active Sephadex LH20 fractions.
6.2 Purification of the light-petroleum extract
Introduction
As described above, relatively apolar fractions of the Silica column separation of the
diethyl ether extract showed complement inhibition as well. TLC analysis revealed the
presence of similar compounds in the light petroleum extract. Therefore, this extract was




TLC analysis was carried out on precoated Si60 F254 Silica plates (Merck). Typically,
10 µl solution was applied to the plate and dried. The plate was developed in a saturated
chamber with a mixture of cyclohexane and acetone in a ratio of 3: 1 and sprayed with a 1:
1 mixture of vanillin (1 % w/v in ethanol) and sulfuric acid (5 % v/v in ethanol). Colored
spots were detected after heating for 5 min at 110 °C.
Silica column chromatography and Sephadex LH20 chromatography
A Silica column separation was performed (column size 50 cm × 5 cm diameter),
similar to the one described above, but with light petroleum extract as the starting material.
The extract (1 g) was eluted with diethyl ether: ethyl acetate in a ratio of 1: 1, and 19
fractions of 100 ml were collected. The remaining material on the column was eluted with
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1000 ml dried methanol, yielding fraction 20. All fractions were dried and tested on weight
base in the complement assay. Active fractions (4-6) were pooled (130 mg) and further
purified by Silica LowBar chromatography.
Silica LowBar chromatography, and preparative TLC
Active fractions of the Silica separation described previously (130 mg) were subjected
to Silica LowBar column chromatography using cyclohexane: acetone in a ratio of 8: 2 as
eluent. Fourty fractions of 8 ml were collected, analyzed by TLC, and tested in the
complement assay. Based on similarity in TLC profile and activity, fractions 11-15 were
pooled as well as fractions 17-23. These fractions were applied to preparative TLC plates
and developed using cyclohexane: methanol in a ration of 3: 1 as eluent. Fluorescent bands
(360 nm) were scraped off and extracted three times with cyclohexane: acetone in a ratio
of 8: 2. The respective extracts were pooled and filtrated. Filtrates were dried, analyzed by
TLC, and tested on weight base for complement depletion.
Results and discussion
Light-petroleum Soxhlet extract of rhizomes of P. scrophulariiflora was obtained as
described in chapter 5. Separation of this extract using Silica column chromatography with
diethyl ether: ethyl acetate as eluent yielded active fractions with a similar TLC profile and
activity to fraction 3-4 of the previously described Silica column separation of the diethyl-
ether extract (figures 2 and 7). Fractions 4-6 were pooled (13 % yield over one step) and
further separated on a Silica LowBar column with cyclohexane: acetone in a ratio of 8: 2 as
eluent (figure 6).
Figure 6. Purification scheme of fractions from the light petroleum extract inhibiting the
classical pathway of complement activation.
All fractions were tested and showed two separate groups of active fractions, which
seemed to consist of at least two active compounds each (figure 8). Fractions 11-15 were
pooled, as well as fractions 17-23, and these were separated by preparative TLC.
Fluorescent bands were scraped off, extracted, and tested for anticomplementary activity
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(figures 9 and 10). Band 3 of fractions 11-15 showed highest activity (IC50 = 0.5 ± 0.2
µg/ml). This fraction revealed at least 8 spots on TLC analysis, some of them coinciding
with phytosterols, according to color and Rf value after detection. Further research is being
























Figure 7. Inhibition of the classical pathway of complement activation by fractions


















Figure 8. Volume-based inhibition of complement activation by Silica LowBar fractions
obtained by Silica-column chromatography.




















Figure 9. Inhibition of the classical pathway of complement activation by fractions
obtained by preparative TLC of active LowBar fractions 11-15. Data were expressed as





















Figure 10. Inhibition of the classical pathway of complement activation by fractions
obtained by preparative TLC of active LowBar fractions 17-23. Data were expressed as
means ± SEM of two duplicate experiments.
Several methods have been followed in order to isolate compounds from P.
scrophulariiflora that inhibit complement activation, and a representative overview is
presented in this chapter. It has become clear that in both the light petroleum and the
diethyl ether extracts several compounds are present, which potently inhibit the classical
pathway of complement activation. It seems, however, that the respective amounts of these
compounds in the extracts are rather low. Furthermore, the difficulty to purify active
compounds suggests that many compounds are present with similar physical properties, at
least with respect to their solubility and absorption in the separation systems used. This has
made isolation very tedious and incomplete within the time span available. However, TLC
analysis suggested the presence of phytosterols in the light petroleum extract. Although
these compounds have not been demonstrated in Picrorhiza species before, stigmasterol,
campesterol, and β-sitosterol are ubiquitous in higher plants and are known for their potent
complement-depleting activity (Yamada et al., 1987, Oh et al., 1998).
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In conclusion, P. scrophulariiflora light petroleum and diethyl ether extracts contain
several compounds that inhibit the classical pathway of complement activation. More
research will be required to isolate these compounds and to elucidate their structure.
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Introduction
T-lymphocytes are among the key players in cell-mediated immunity. In order to
generate an effective immune response, activation and subsequent expansion of antigen-
specific lymphocytes is required. Activation of T cells initiates when T-cell receptors
(TCRs) bind to specific antigens, in association with major histocompatibility complex
(MHC) molecules on the membrane of antigen-presenting cells (APC). Several other
proteins and receptors are associated with the TCR and play a cooperative role in a
controlled manner of signal transduction (Abraham et al., 1992, Chambers and Allison,
1997, 1999). A persistent stimulatory signal ultimately leads to the expansion and
differentiation of the specific T cells, under the influence of an array of cytokines and
growth factors (Swain, 1999). Activated T-cells have been implicated as important
mediators in inflammation and in the pathogenesis of autoimmune diseases such as
rheumatoid arthritis (Maini et al., 1995, Perkins, 1998). Several compounds that suppress
pro-inflammatory T cells have been successfully used in the treatment of rheumatoid
arthritis, e.g. azathioprine (Berry et al., 1976), chloroquine (Landewé et al., 1995),
methotrexate (Boerbooms et al., 1988), cyclosporin (Van Rijthoven et al., 1986), and
glucocorticoids (Kirwan, 1995). However, toxicity induced by these drugs stresses the need
for new therapeutics in the treatment of autoimmune diseases.
Along this line, our research is aiming at the disclosure of compounds that interfere
with the proliferation of lymphocytes. As described in the previous chapter, a diethyl ether
Soxhlet extract of Picrorhiza scrophulariiflora Pennell strongly inhibited T-cell
proliferation, while other extracts were not active. This chapter describes the isolation and




RPMI 1640 medium, fetal calf serum (FCS), and M199 medium were obtained from
Gibco BRL, Life Technologies (Paisley, Scotland); Phytohemagglutinin (PHA) from
Murex Diagnostics (Dartford, GB); Concanavalin A type IV, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), 5-carboxyfluorescein diacetate (CFDA), and
propidium iodide (PI) from Sigma Chemicals (St. Louis MO, USA). Lactate
dehydrogenase (LDH) substrate mixture consisted of 1 mg NAD (β-nicotinamide adenine
dinucleotide ⋅ 4H2O; Janssen Chimica, Geel, Belgium), 80 µg phenazine methosulphate
(Janssen Chimica), 4.8 mg calcium lactate, and 0.5 mg MTT per ml 0.2 M Tris buffer
(tris(hydroxymethyl)aminomethane; Merck, Darmstadt, Germany), adjusted to pH 7.2.
Silica 60 was obtained from Merck, and Sephadex LH20 from Pharmacia (Uppsala,
Sweden).
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Analytical methods
TLC analysis was carried out on precoated Si60 F254 Silica plates (Merck). Typically,
10-µl solutions were applied to the plate and dried. The plate was developed in a saturated
chamber with a mixture of ethyl acetate, methanol, and water in a ratio of 20: 3: 2, and
sprayed with a 1: 1 mixture of vanillin (1 % w/v in ethanol) and sulfuric acid (5 % v/v in
ethanol). Colored spots were detected after heating for 5 min at 110 °C.
HPLC separation was performed on a modular Gilson (Middleton, USA) system (dual
306 pumps, 234 auto injector, 170 diode array detector, FC 204 fraction collector) provided
with UniPoint software (v. 1.65) for automated sample handling. For preparative HPLC, an
Alltech Adsorbosphere Silica column (Deerfield, USA; 5 µm, 250 x 10 mm) was used, and
a gradient of cyclohexane and ethanol (0-2 min: 100 %; 2-10 min: 100 % → 93 %; 10-24
min: 93 %; 24-30 min: 93 % → 100 %). For analytical HPLC, an Alltech Alltima C18
column (5 µm, 250 x 4.6 mm) was used, and a gradient of water and acetonitrile (0-5 min:
90 %; 5-10 min: 90 % → 80 %; 10-25 min: 80 %; 25-40 min: 80 % → 20 %).
Pilot purification procedure
Diethyl-ether Soxhlet extract of rhizomes of P. scrophulariiflora was obtained as
described in chapter 6. Dried extract (190 mg) was dissolved in 10 ml of a mixture of
diethyl ether and ethyl acetate in a ratio of 1: 1 and subjected to Silica column
chromatography (50 cm × 2 cm diameter). Diethyl ether: ethyl acetate (1: 1) served as
eluent and 6 fractions of 50 ml and 4 fractions of 100 ml were collected. All fractions were
dried, analyzed by TLC, and tested for antiproliferative activity.
Isolation procedure of compound 1
Diethyl-ether extract (2.5 g) was subjected to Silica column chromatography (50 cm ×
5 cm diameter) with diethyl ether: ethyl acetate (1: 1) as eluent. Thirty fractions of 100 ml
were collected, three times concentrated, analyzed by TLC, and tested on volume base for
antiproliferative activity. Compound 1 was directly obtained from fractions 18-30 (300 mg)
by crystallization (50 mg; 0.04 % of dried rhizomes).
Isolation procedure of compound 2
Active fractions 10-13 of the previous described Silica column separation were pooled
(200 mg) and pooled with the corresponding fractions of a similar separation. These
fractions (370 mg) were separated by Sephadex LH20 (50 cm × 2 cm diameter) with
acetone as eluent. Sixty fractions of 400 drops (ca. 8 ml) were collected and concentrated
three times. Even fractions were analyzed by TLC and odd fractions were tested for
antiproliferative activity. Fractions corresponding in TLC profile and activity (18-26) were
pooled (150 mg) and further purified by preparative HPLC using a gradient of cyclohexane
and ethanol, yielding compound 2 (40 mg; 0.02 % of dried rhizomes).
Purification of unknown compound
The active fractions 1-9 of the previously described Silica separation of the diethyl-
ether extract were pooled (1.3 g) and further purified by Sephadex LH20 with acetone as
eluent. Fifty fractions of about 10 ml were collected, three times concentrated, analyzed by
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TLC, and tested on volume base in the T-cell proliferation assay. Fractions 6-11 were
pooled (100 mg) because they showed antiproliferative activity and a similar TLC profile.
The pooled fractions were subjected to Sephadex LH20 separation using dichloromethane
(DCM) as eluent, yielding 40 fractions. The fractions were three times concentrated, odd
fractions being analyzed by TLC, and the even fractions being tested on volume base in the
T-cell proliferation assay.
Structure elucidation
The structures of compounds 1 and 2 were determined using EI-MS, FAB-MS, IR, 1H
NMR, and 13C NMR spectroscopy (including APT, COSY and HETCOR).
T-cell proliferation assay
The T-cell proliferation assay was performed as described in chapter 6.
T-cell toxicity assays
For the assessment of cytotoxic effects of picracin and deacetylpicracin towards T-
lymphocytes, LDH-release (Babson and Phillips, 1965), and CFDA/PI-labeling (Bruning et
al., 1980) assays were performed. Cell suspensions (50 µl) were incubated at 37 °C in U-
well microtiter plates with 50 µl medium and appropriate dilution ranges of test samples.
To determine the amount of LDH released after 24 h, plates were spun (5 min, 300 × g),
supernatants (50 µl) were transferred to flat-bottom microtiter plates, and 25 µls of LDH
substrate mixture were added. After incubation (10 min, 37 °C), the optical densities at 550
nm were measured. Controls consisted of cells incubated with test samples and 50 µl
Triton X-100 (0.1 % v/v), cells incubated with 50 µl Triton X-100 (0.1 % v/v), or cells
incubated with medium only.
To assess cytotoxicity after 4 days, stimulated lymphocytes were labeled with
carboxyfluorescein (CFDA) and propidium iodide (PI) to distinguish viable from dead
cells. After 4 days of incubation (37 °C), 50 µl of a 1 µl/ml CFDA dilution in RPMI
medium was added. After incubation in the dark (15 min, room temperature), 50 µl PI in
ink was added. The plates were inspected under an upside-down fluorescence microscope
and the ratio of viable/dead cells was assessed. Controls consisted of cells incubated with
medium only.
Results and discussion
Two cucurbitacins were isolated from the rhizomes of P. scrophulariiflora, guided by
inhibition in a mitogen-induced human T-lymphocyte proliferation assay. The diethyl-ether
extract, which potently inhibited proliferation (IC50 = 13 ± 2 µg/ml), was subjected to
Silica column chromatography using a mixture of diethyl ether and ethyl acetate in a ratio
of 1: 1 as eluent. TLC analysis of the fractions showed a good separation with major blue
spots at Rf = 0.70 and Rf = 0.65 in fractions 4-5 and 6-7, respectively. The fractions were
tested on a weight base in the T-cell proliferation assay, revealing high activity for the
fractions 4-7 (figure 1).

























Figure 1. Inhibition of proliferation of T cells by Silica fractions of the diethyl ether (DE)
extract of P. scrophulariiflora. Data were expressed as means ± SEM of 2 experiments.
In order to obtain higher yields, a similar separation as described earlier was used with
a larger Silica column. The fractions were tested in the T-cell proliferation assay, in which
two groups of fractions revealed inhibitory activity (figure 2). Fractions 1-9 were pooled
since they showed a similar TLC profile. The pooled fractions were subjected to Sephadex
LH20 chromatography using acetone and dichloromethane as eluents, respectively (figures
4 and 5). However, this method did not result in a good separation, and revealed at least
eight different compounds in the active fractions 13-24 of the dichloromethane separation,
as shown by TLC analysis. Because more material was needed to isolate the active
compound, priority was given to the other fractions (figure 3).
Fractions 10-13 of the Silica column separation (figure 2) were pooled and subjected
to Sephadex LH20 column chromatography using acetone as eluent. Fractions 18-26 were
pooled, based on their TLC profile and activity (figure 6), and subjected to HPLC using a
gradient of cyclohexane and ethanol. The major peak yielded compound 2, which potently
inhibited T-cell proliferation.
Fractions 18-30 of the Silica column separation (figure 3) showed a similar TLC
profile, revealing a blue spot at Rf = 0.66, which corresponded to the spot observed with
fractions 6-7 of the pilot separation (figure 1). Repetitive crystallization from the pooled
fractions yielded a pure compound (1), which also potently inhibited T-cell proliferation.



















Figure 2. Volume-based inhibition of T-cell proliferation by Silica fractions of the diethyl
ether extract.
Figure 3. Isolation scheme of picracin and deacetylpicracin from rhizomes of P.
scrophulariiflora.


















Figure 4. Volume-based inhibition of fractions obtained by separation of Silica fractions 1-


















Figure 5. Volume-based inhibition of fractions obtained by separation of LH20-acetone
fractions 6-11 on LH20 using DCM as eluent.

















Figure 6. Volume-based inhibition of Sephadex LH20 fractions of Silica fractions 10-13,
containing compound 2.
Both compounds were identified as aglycones of known 11-deoxycucurbitacin
glucosides (Laurie et al., 1985, Stuppner and Wagner, 1989) and named deacetylpicracin
(1) and picracin (2). Using TLC, they revealed blue spots with Rf values of 0.65 and 7.0,
respectively. Their structures were determined by EI-MS, FAB-MS, IR, 1H NMR, and 13C
NMR spectroscopy (including APT, COSY and HETCOR). Deacetylpicracin (1) was
obtained as colorless needles (ethyl acetate): mp 224-228 °C (decomposition); IR (KBr)
νmax 3400, 2939, 1682, 1633, 1282 cm-1; FAB-MS m/z 505 [M+H]+. Picracin (2) was
obtained as colorless amorphous powder: mp 181-182 °C; IR (KBr) νmax 3575, 2947, 1716,
1672, 1618, 1258 cm-1; EI-MS m/z 486 [M-CH3COOH]+ (1.5), 96 (100).
Picracin was shown to be 25-acetoxy-2,3,16,20-tetrahydroxy-9-methyl-19-norlanosta-
5,23-diene-22-one (2, figure 2) which was reported previously being an aglucone obtained
by hydrolysis of  the corresponding 2-O-β-D-glucoside isolated from P. kurrooa (Laurie et
al., 1985).
The 1H NMR spectrum of deacetylpicracin (2,3,16,20,25-pentahydroxy-9-methyl-19-
norlanosta-5,23-diene-22-one; 1, figure 2) showed the characteristic signals of an 11-
deoxycucurbitacin skeleton with signals for eight methyl groups between 0.85 and 1.29
ppm and three olefinic protons at δ 5.49 (H-6, d, J = 5.5 Hz), 6.69 and 6.87, the latter two
signals being an AB system (H-24, H-23, d, J = 15.4 Hz) attributable to the α,β-
unsaturated ketone function of the side chain. In addition, signals at δ 3.29, 3.88, and 4.32
were assigned to three single protons being attached to hydroxylated carbons. 1H-1H COSY
experiments showed the coupling of a broad doublet at δ 3.88 (H-2, J = 10.7 Hz) to a
doublet at δ 3.29 (H-3, J = 2.2 Hz). The triplet at δ 4.32 was assigned to H-16 (J = 7.5 Hz).
Compared with the 1H NMR spectrum of picracin, the methyl groups at C-25 (26-Me and
27-Me) were shifted upfield to δ 1.22 (- 0.2 ppm), whereas the signal for OCOMe at δ 1.90
was missing, indicating the absence of the C-25 acetyl group.
Activity-guided isolation of cucurbitacins inhibiting T-cell proliferation |  105
In addition, it was shown by TLC analysis that methanolysis of picracin with sodium
methoxide resulted in the formation of deacetylpicracin.
Table 1. 1H NMR data (ppm) of 1 and 2 in CD3OD and CDCl3 (300 MHz); J is expressed
in Hz; s = singlet, d = doublet, t = triplet, br. = broad.
δ (1) CD3OD δ (2) CD3OD δ (2) CDCl3*
0.85 (3H, s) 0.84 (3H, s) 0.90 (3H, s)
0.93 (3H, s) 0.92 (3H, s) 1.00 (3H, s)
0.96 (3H, s) 0.92 (3H, s) 1.04 (3H, s)
1.02 (3H, s) 1.00 (3H, s) 1.04 (3H, s)
1.07 (3H, s) 1.06 (3H, s) 1.16 (3H, s)
1.29 (3H, s) 1.29 (3H, s) 1.39 (3H, s)
H-26 1.22 (3H, s) 1.46 (3H, s) 1.51 (3H, s)
H-27 1.22 (3H, s) 1.44 (3H, s) 1.51 (3H, s)
OCOMe 1.90 (3H, s) 1.97 (3H, s)
H-17 2.25 (d, J = 7.0)
H-3 3.29 (1H, d, J = 2.2) 3.29 (1H, s) 3.43 (1H, br.s)
H-2 3.88 (1H, br.d, J = 10.7) 3.87 (1H, br.d, J = 11.7) 3.96 (1H, br.d, J = 11.7)
H-16 4.32 (1H, t, J = 7.5) 4.38 (1H, t, J = 7.9) 4.30 (1H, br.)
H-6 5.49 (1H, d, J = 5.5) 5.48 (1H, d, J = 5.1) 5.62 (1H, d, J = 5.5)
H-23 6.69 (1H, d, J23-24 = 15.4) 6.68 (1H, d, J23-24 = 15.8) 6.44 (1H, d, J23-24 = 15.7)
H-24 6.87 (1H, d) 6.87 (1H, d) 7.00 (1H, d)
* Values are in agreement with Laurie et al., 1985.
The 13C NMR spectrum of deacetylpicracin was very similar to that of picracin except
for some signals of the side chain. In contrast to picracin, only one carbonyl carbon signal
was found (C-22 at δ 204.8), the signal for C-24 being shifted downfield to 155.3 (+ 5.7
ppm), whereas the signal for C-25 showed a strong upfield shift to 70.1 (- 9.6 ppm). In
addition, the absence of the acetyl group at C-25 was confirmed by the mass difference of
42 between picracin and its deacetylated derivative. Compared with its 2-O-β-D-glucoside
(Stuppner and Wagner, 1989), the signal of C-2 in the 13C NMR spectrum of
deacetylpicracin in CD3OD showed a strong upfield shift (about - 8 ppm), whereas signals
of C-1 and C-3 shifted to a lower field (about + 2-3 ppm). These observations are in good
agreement with picracin and its 2-O-β-D-glucoside (Stuppner and Wagner, 1989) and with
literature data reported for the 23,24-dihydro derivative of deacetylpicracin and a series of
2-O-β-D-glucosides of related aglucones (Stuppner et al., 1991).
Concerning the stereochemistry of deacetylpicracin, the coupling constant of 2.2 Hz
between H-2 and H-3 indicated a 2β,3β-diol configuration since 2α,3α-diol systems have
not been found in natural cucurbitacins so far (Rao et al., 1974, Che et al., 1985, Laurie et
al., 1985). In analogy with other cucurbitacins, it was assumed that the 20-OH of
deacetylpicracin is β-oriented, whereas the 16-OH is in the α-position (Vande Velde and
Lavie, 1983, Stuppner et al., 1991). The α-orientation of 16-OH and the β-orientation of
20-OH have been confirmed by X-ray crystallographic analysis of (20R)-16α-acetoxy-20-
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hydroxy-24,25,26,27-tetranor-2β-(β-D-tetraacetylglucopyranosyloxy)-10α-cucurbit-5-en-
3,11,22-trion, a derivative of a cucurbitacin obtained from P. kurrooa, and the di-p-
iodobenzoate of datiscoside, a cucurbitacin isolated from Datisca glomerata
(Cucurbitaceae) (Kupchan et al., 1972, Weinges et al., 1989).









C-1 CH2 30.5 31.9 30.5 31.9
C-2 CH 69.9 68.9 69.9 68.9
C-3 CH 80.4 79.8 80.4 79.8
C-4 C 42.6 41.9 42.6 41.9
C-5 C 141.9 142.0 141.9 142.0
C-6 CH 121.5 119.8 121.7 119.8
C-7 CH2 25.2 24.5 25.3 24.5
C-8 CH 44.1 42.7 44.1 42.8
C-9 C 35.3 34.4 35.3 34.5
C-10 CH 38.3 37.2 38.2 37.3
C-11 CH2 31.5 30.5 31.3 30.6
C-12 CH2 32.9 30.7 32.8 30.6
C-13 C † 46.7 49.5 46.6
C-14 C 49.9 48.9 49.7 48.9
C-15 CH2 47.0 48.9 46.9 48.8
C-16 CH 72.4 70.9 72.6 71.2
C-17 CH 60.0 59.6 60.5 60.1
C-18 CH3 18.6 18.4 18.7 18.4
C-19 CH3 29.2 29.8‡ 28.4 27.9‡
C-20 C 80.5 79.6 81.1 80.1
C-21 CH3 25.1 25.2‡ 24.9 25.2‡
C-22 C 205.4 204.8 205.6 204.7
C-23 CH 121.7 121.0 123.0 122.7
C-24 CH 155.3 155.3 151.4 149.6
C-25 C 71.6 70.1 80.9 79.7
C-26 CH3 29.2 29.5! 26.5 26.0‡
C-27 CH3 28.5 27.9‡ 26.8 26.5‡
C-28 CH3 27.5 27.2‡ 27.5 27.2‡
C-29 CH3 26.1 26.2‡ 26.1 26.2‡
C-30 CH3 19.2 18.4 19.2 18.5
OCOMe, C 172.0 169.8
OCOMe, CH3 21.8 21.5
† Signal obscured by the solvent signal; ‡ tentatively assigned.







1: R = OH
2: R = OAc
Figure 7. Cucurbitacins isolated from P. scrophulariiflora with T-cell antiproliferative
activity (1: deacetylpicracin; 2: picracin).
Table 3. Contents of picracin and deacetylpicracin in Soxhlet extracts of P.
scrophulariiflora.
Picracin Deacetylpicracin
Ps.PE 0.69 ± 0.20 % nd
Ps.DE 4.5 ± 1.3 % 3.2 ± 0.7 %
Ps.EA nd nd
Ps.Me 0.19 ± 0.00 % nd
Ps.Aq nd nd
Pk = P. kurrooa; Ps = P. scrophulariiflora; nd = not detectable.
The contents of picracin and deacetylpicracin were determined in the extracts prepared,
and were found to be 4.5 % and 3.2 % (v/v), respectively. Furthermore, picracin was detected
in the light-petroleum extract and the methanol extract (table 3).
Both compounds exhibited a dose-dependent inhibition of PHA-induced T-cell
proliferation. The IC50 values were determined to be 1.0 ± 0.2 µM for both picracin and
deacetylpicracin.









Figure 8. Effects of diethyl ether (DE) extract, picracin, and deacetylpicracin (DAP) on
PHA-induced proliferation of T cells. Data were expressed as means ± SEM of at least 9
experiments.
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Because cucurbitacins are well known for their cytotoxic behavior (Fuller et al., 1994),
cytotoxic properties of the two compounds were determined. Labeling the PHA-stimulated
lymphocytes after 4-day incubation with carboxyfluorescein diacetate and propidium
iodide to distinguish between viable and dead cells, showed only minor cell death (< 10 %)
for concentrations of picracin and deacetylpicracin below 60 µM. Another cytotoxicity
experiment, using the lactate dehydrogenase release assay, did not show any toxic effect up
to 50 µM for both cucurbitacins after 24 h. As these concentrations are much higher than
the IC50 values of both compounds (1 µM), it can be concluded that the inhibitory activity
of picracin and deacetylpicracin is most probably not to be ascribed to cytotoxic effects.
Several cucurbitacins have been shown to inhibit incorporation of radioactive
precursors into DNA, RNA, and protein of HeLa S3 cells at ID50 values that were similar
to the ED50 values of cucurbitacin-induced growth inhibition of these cells. This suggests a
relationship between the inhibition of intracellular metabolic activity and growth-inhibitory
activity (Witkowski et al., 1984). Furthermore, cucurbitacin E was shown to induce
morphological changes and inhibit cell growth of prostrate carcinoma cells and human
endothelial cells, which were associated with the disruption of the filamentous (F)-actin
cytoskeleton (Duncan et al., 1996, Duncan and Duncan, 1997). The cytoskeleton has been
implicated as a critical intermediate in signal transduction pathways controlling cell
division (Luna and Hitt, 1992, Penninger and Crabtree, 1999). Therefore, the mechanism of
picracin and deacetylpicracin may also include interference with the cytoskeleton and
subsequent abrogation of proliferative signal transduction, leading to inhibition of T-cell
proliferation.
In conclusion, picracin and deacetylpicracin, two cucurbitacins isolated from P.
scrophulariiflora, are potent inhibitors of mitogen-induced proliferation of T lymphocytes.
These findings may explain the usefulness of P. scrophulariiflora in the treatment of
diseases such as asthma, jaundice, and arthritis (chapter 3), in which T cells play a pivotal
role (Walker et al., 1991, Löhr et al., 1996, Klimiuk et al., 1999). In addition, picracin and
deacetylpicracin may serve as lead compounds for the development of future anti-
inflammatory drugs.
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Introduction
In the previous chapter, the isolation of two bioactive cucurbitacins from the rhizomes
of Picrorhiza scrophulariiflora was described. Both compounds potently inhibited
mitogen-induced proliferation of T cells. In this chapter, experiments are delineated that
pertain to the underlying mechanisms of this immunomodulatory effect.
As described in chapter 5, the activation of T cells requires signal transduction that
leads to the release of IL-2 and the expression of IL-2 receptor (IL-2R), ultimately leading
to proliferation. In normal situations, cell proliferation and cell death are in balance.
However, autoimmune diseases are associated with an increased survival of potentially
autoreactive T lymphocytes. Activated T lymphocytes that are differentiated into pro-
inflammatory effector cells release cytokines, which sustain cell-mediated immune
responses (Swain, 1999). Within the articular synovium, these T cells activate synovial
macrophages that produce a range of pro-inflammatory cytokines, which induce
proliferation of synoviocytes, enhancing the local inflammatory process. These involve
lymphocytes, chondrocytes, fibroblasts, and osteoclasts, inducing damage of bone,
cartilage, and other connective tissue components (Feldmann et al., 1996, Vaishnaw, et al.,
1997, Starkebaum, 1998).
Therapeutic measures of rheumatoid arthritis (RA) often focus on immunomodulatory
activity, by means of nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or
disease-modifying antirheumatic drugs (DMARDs; AMR, 1996a). While NSAIDs only
afford symptomatic relief, without altering the course of the disease or preventing joint
damage, glucocorticoids and DMARDs interfere with the release of pro-inflammatory
cytokines. As such, they have the potential to reduce and prevent joint damage and to
preserve joint integrity and function (Shevach, 1995, Cronstein, 1996). A major
disadvantage of these drugs, however, is their toxicity, which is usually proportional to
their efficacy (AMR, 1996b, Jackson and Williams, 1998). These side effects imply an
ongoing search for lead compounds that are able to selectively interfere with pathological
processes underlying chronic inflammation.
8.1 In vitro immunomodulatory effects on T lymphocytes and monocytes
Materials and methods
Materials
Picracin and deacetylpicracin were isolated from P. scrophulariiflora Pennell as
described earlier (chapter 7). Cucurbitacin E was obtained from Extrasynthese (Genay,
France). M199 medium, RPMI 1640 medium, and heat-inactivated fetal calf serum (FCS)
were obtained from Gibco BRL, Life technologies (Pailsey, Scotland);
Phytohemagglutinin (PHA) from Murex Diagnostics (Dartford, GB); 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 5-carboxyfluorescein
diacetate (CFDA), propidium iodide (PI), and cyclophosphamide from Sigma Chemicals
(St. Louis MO, USA); and sodium dodecyl sulphate (SDS) from ICN Biomedicals. Sheep
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red blood cells (SRBC) were obtained from citrated arterial blood supplied by Charles
River (Someren, The Netherlands) and were washed thrice before use.
IL-2 release
Peripheral blood lymphocytes (PBLs) were prepared from buffycoat residues, kindly
provided by the Blood bank Midden-Nederland (Utrecht, Netherlands), using Ficoll-
Hypaque centrifugation, according to the supplier’s intructions (Amersham Pharmacia).
Cells were diluted to 2⋅106 cells/ml RPMI 1640 supplemented with 10 % FCS and
dispensed in 96-wells microtiter plates (50 µl/well). Proliferation was induced using 50 µl
PHA (0.1 mg/ml), and cells were incubated at 37 °C with 50 µl of test samples in
appropriate dilution ranges. After incubation, 50-µl samples of supernatants were
transferred to flatbottom plates and IL-2 levels were determined using an ELISA-kit (CLB,
Amsterdam, Netherlands). Controls consisted of stimulated PBLs without sample (100%
activity), non-stimulated PBLs without sample (0% activity), and non-stimulated PBLs
with samples.
Pro-inflammatory cytokine release
Mononuclear cells were obtained from buffycoat residues (Bloedbank Midden-
Nederland) using Ficoll-Hypaque centrifugation, according to the manufacturer’s
instructions (Amersham Pharmacia). Under sterile conditions, 100-µl samples of cell
suspension were dispensed in 96-wells flatbottom microtiter plates, and monocytes were
allowed to adhere overnight at 37 °C under 5 % CO2-atmosphere in a humidified
incubator, at a concentration of 106 cells/ml M199. After removal of non-adhering cells,
50-µl sample solutions in appropriate dilution ranges were added. Cells were stimulated by
adding 50 µl LPS (0.5 µg/ml M199 medium), and incubated overnight at 37 °C under 5 %
CO2 atmosphere in a humidified incubator. After incubation, 50-µl samples of supernatants
were transferred to flatbottom microtiter plates, and used for the detection of IL-1β and
TNFα, using ELISA-kits (CLB, Amsterdam, Netherlands). IC50-values of the test
compounds were calculated in µg/ml. Controls consisted of non-stimulated cells incubated
with sample solutions.
Toxicity assays
For the assessment of cytotoxic effects of picracin and deacetylpicracin, cells were
labeled with CFDA and PI to distinguish between viable and dead cells. After 4 days of
incubation (37 °C), 50 µl of a 1 µl/ml CFDA dilution in RPMI medium was added. After
incubation in the dark (15 min, room temperature), 50 µl PI in ink was added. The plates
were inspected under an upside-down fluorescence microscope and the ratio of viable/dead
cells was assessed. Controls consisted of cells incubated with medium only.
Apoptosis
PBLs (2 × 106 /ml), obtained as described above, were added to equal volumes of
picracin or deacetylpicracin in different concentrations and incubated in a humidified
incubator (36 °C). After incubation, cells were washed with phosphate-buffered saline
(PBS) and incubated shed from light for 15 min in binding buffer containing FITC-
conjugated annexin V (1:100). Propidium iodide (PI; 10 µg/ml) was added just before
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analysis to detect dead cells. T cells were detected using FITC-conjugated anti-CD3
antibodies (1:100). Fluorescence of stained cells were measured by flow cytometry on a
FACScan apparatus (Becton Dickinson) and analyzed with WinMDI (vs. 2.8; Scripps
Institute, La Jolla, USA).
T cells that were annexin V positive and PI negative were regarded as apoptotic cells.
Results
IL-2 release
Control experiments revealed maximum IL-2 release by PHA-activated T cells about
24 h after activation. This incubation time was used in determining the effects of picracin
and deacetylpicracin on IL-2 release of activated PBLs. Picracin, deacetylpicracin, and
cucurbitacin E inhibited IL-2 release by activated T cells after 24 h at IC50 values of 5 ± 2
µM, 16 ± 7 µM, and 5 ± 1 µM, respectively (figure 1). Activated T cells that were stained
with CFDA and PI, following exposure to either of the compounds, revealed a direct toxic
effect of cucurbitacin E, while cells treated with picracin or deacetylpicracin did not differ
substantially from controls, as estimated by with fluorescent microscopy.










Figure 1. Effects of picracin, deacetylpicracin (DAP), and cucurbitacin E (cuc E) on IL-2
release by PHA-activated T lymphocytes after 24 h incubation, as determined by ELISA.
Data were expressed as means ± SEM of 6 (picracin) or 3 (DAP and cuc E) separate
experiments.
IL-1β, TNFα release
To investigate additional immunomodulatory activities of picracin and DAP on the
development of chronic inflammation, we assessed the effect of both compounds on the
release of pro-inflammatory cytokines by monocytes. After stimulation of monocytes with
LPS, cells were incubated for 24 h with different concentrations of picracin or DAP. Upon
analysis of the supernatants of these cells, using ELISA, we found that picracin inhibited
the release of both IL-1β and TNFα at IC50-values of 7 ± 2 µM and 10 ± 4 µM,
respectively. Cucurbitacin E inhibited TNFα release more potently (IC50 = 3 ± 2 µM),
while IL-1β-inhibiting activity was a factor 5 lower (IC50 = 16 ± 3 µM). Contradictory,
deacetylpicracin did not show inhibitory activity on the release of IL-1β up to 200 µM, the
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highest concentration tested, while it moderately inhibited TNFα release (IC50 = 120 ± 36
µM). Dexamethasone showed similar activity as deacetylpicracin (figure 3). Staining of
activated monocytes, exposed to either of the compounds, with CFDA and PI, did not
















Figure 2.  Effects of picracin, deacetylpicracin (DAP), cucurbitacin E, and dexamethasone
on the release of pro-inflammatory cytokines by LPS-activated monocytes. Data were
expressed as means ± SEM of 6 (picracin and DAP) or 3 (cucurbitacin E and
dexamethasone) separate experiments.
Apoptosis of T cells
To assess whether picracin and deacetylpicracin were able to induce apoptosis in non-
stimulated T cells, PBLs were exposed to the two compounds. After incubation for 2, 4, 6,
or 24 h, cells were stained with FITC-conjugated annexin V and propidium iodide (PI) and
analyzed by flow cytometry. Stained cells that were annexin V-positive and PI-negative
were regarded as apoptotic. Flow cytometric analysis of stained T cells that were exposed
to picracin, showed a significant induction of apoptosis (70-85 % of gated T cells) after 4,
6, and 24 h, at concentrations of 20 µM and 200 µM (figure 2A). Deacetylpicracin,
however, only slightly induced apoptosis (30-35 %) after 4, 6, and 24 h, at 200 µM, the
highest concentration tested (figure 2).
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Figure 3. Flow-cytometric analysis of picracin- (A) and deacetylpicracin (DAP; B)-
induced apoptosis in non-stimulated T-cells. After incubation, cells were stained with
FITC-conjugated annexin V (FL1; x-axis) and propidium iodide (FL2; y-axis). Results are
representative of two separate experiments. C. Percentage of T cells treated with picracin
or deacetylpicracin (DAP) undergoing apoptosis (annexin-V positive and propidium iodide
negative). Data were expressed as means ± SEM of two separate experiments and
statistically analyzed by Student’s t-test. P-values are < 0.05 (*).
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Discussion
In the previous chapter, the isolation of two cucurbitacins that inhibit T-cell
proliferation from rhizomes of Picrorhiza scrophulariiflora was described. In this chapter,
possible underlying mechanisms are investigated. As described earlier, proliferation of
activated T-cells is mediated by the release of IL-2 and the subsequent interaction with the
IL-2 receptor (IL-2R), which is only expressed in T cells that are activated. Control
experiments show that IL-2 release by mitogen-activated peripheral blood T lymphocytes
is optimal at 24 h after induction, which is in agreement with literature (Swain, 1999).
Incubation of activated T cells with picracin or deacetylpicracin showed a marked
inhibition of IL-2 release after 24 h, at IC50 values of 5 and 16 µM, respectively, which
could not be ascribed to a direct toxic effect. Furthermore, cucurbitacin E, a cucurbitacin
known to inhibit the proliferation of endothelial cells (Duncan and Duncan, 1997),
inhibited IL-2 release at an IC50 value of 5 µM. However, fluorescence microscopical
analysis following staining of cells with CFDA and PI demonstrated that in this case a
direct cytotoxic effect was involved. These data may explain the antiproliferative activity
of picracin and cucurbitacin, since IL-2 is responsible for signaling T-cell proliferation
(Smith, 1988). The difference observed between picracin and deacetylpicracin regarding
inhibition of IL-2 release might be ascribed to differences in lipophility between the two
compounds.
In addition to the effects on T lymphocytes, the effects of picracin and
deacetylpicracin on the release of the pro-inflammatory cytokines IL-1β and TNFα by
activated monocytes was investigated. These cytokines play an important role in the
pathogenesis of RA, because they enhance the release of metalloproteinases by
chondrocytes and fibroblasts, inducing cartilage destruction (Dayer et al., 1986) and
stimulating bone erosion by osteoclasts (Thomas et al., 1987). Incubation of human
monocytes with picracin for 24 h inhibited the release of IL-1β and TNFα at IC50-values of
7 µM and 10 µM, respectively. Deacetylpicracin, however, did not inhibit the release of
IL-1β up to 200 µM, the highest concentration tested, and slightly inhibited TNFα release
(IC50 = 120 µM). Cucurbitacin E, which differs from picracin in the presence of carbonyl
functionalities at C3 and C11, and a C1-2 double bond (chapter 4), inhibited the release of
IL-1β at IC50 = 16 µM and TNFα release at IC50 = 3 µM. This suggests the involvement of
at least the acetyl group in the side chain in the inhibition of IL-1β and TNFα release,
although other functional differences between the two compounds were not taken in
consideration.
The interference of picracin and deacetylpicracin with IL-2 release by activated T
lymphocytes could be the result of a specific interaction with signal transduction pathways
leading to the release of IL-2, or due to the induction of apoptosis, which renders the T cell
incapable of releasing IL-2. To assess the apoptotic effect of picracin and deacetylpicracin,
PBL were stained with FITC-conjugated annexin V, a phospholipid-binding protein with
high affinity to phosphatidylserine, a marker of early apoptosis (Martin et al., 1995,
Vermes et al., 1995). Because phosphatidylserine is exposed in necrotic cells as well, cells
were double stained with propidium iodine (PI). Cells that were annexin V-positive and PI-
negative were regarded as apoptotic. Cytometric analysis of T cells, exposed to picracin,
and stained with annexin V and PI, showed a significant induction of apoptosis (70-85 %)
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after 4, 6, and 24 h, at concentrations of 20 µM and 200 µM. Deacetylpicracin, however,
was about three times less effective, and induced apoptosis for 30-35 % after 4, 6, and 24
h, at 200 µM, the highest concentration tested, which was not significantly different from
untreated cells. Nevertheless, preliminary experiments suggest the induction of apoptosis
in T cells, two days after incubation with deacetylpicracin. The effects observed might be
due to the lower lipophilicity of deacetylpicracin, which could result in a less pronounced
interaction with cell membranes, and, consequently, a delayed capacity to induce
apoptosis. The observation that deacetylpicracin was about three times less effective in
decreasing the release of IL-2 by T cells after 24 h of incubation, while its capacity to
inhibit T-cell proliferation after 4 days of incubation was not inferior to picracin, are in
support of this hypothesis.
8.2 Immunomodulatory effects in vivo
Material, animals, and methods
Animals
Specific-pathogen-free female BALB/c mice of 7-9 weeks were obtained from the
Central Animal Laboratory (Utrecht, The Netherlands), maintained under standard housing
conditions, and provided with food and water ad libitum. At the start of the experiments,
the mice were 8-10 weeks old.
DTH response
Delayed-type hypersensitivity was induced in BALB/c mice according to Kerckhaert
et al. (1974). Before priming, the mice were pretreated with 5 mg cyclophosphamide in
phosphate buffered saline (PBS) intraperitoneally to suppress a B-cell mediated response.
Eight hours after pretreatment, the mice were primed by intraperitoneal injection of 108
SRBC in 200 µl PBS. After 10 days, the mice were challenged by injecting 108 SRBC in
25 µl PBS subplantar in the left paw. Picracin or deacetylpicracin (10, 30, or 100 mg/kg)
was administered, either intraperitoneally 1 hour before challenge (200 µl), or
subcutaneously along with the challenge (25 µl). Dexamethasone served as a positive
control. The locally administered samples, including the controls, contained 20 % DMSO
in order to dissolve the drug properly. A separate control experiment was performed with
primed mice, which were not challenged with antigen, and treated with subcutaneous
injection of picracin or deacetylpicracin (0.1, 1, 10 µg/ml PBS), subplantar in the left paw.
Swelling of the paws was measured 24 h after challenge using a computerized micrometer
device (University Medical Center, Utrecht, The Netherlands), and compared to the control
group. The differences between the experimental groups and the control group were
statistically analyzed using the Students t-test.
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Results
A delayed-type hypersensitivity (DTH) model was used to assess the
immunomodulatory activity of picracin and deacetylpicracin in vivo. Intraperitoneal
injection of sensitized mice, one hour before challenge with either picracin or DAP,
showed significant inhibition of DTH responses for 100 mg/kg picracin (45 %) and for 30
mg/kg DAP (33 %). Dexamethasone (30 mg/kg i.p.) served as a control and inhibited DTH





















Figure 4. Effects of picracin, deacetylpicracin (DAP), and dexamethasone on DTH
responses in mice after intraperitoneal administration. Results are representative of two
independent experiments. Data were expressed as means ± SEM (n = 6 per group) and
statistically analyzed by the Student’s t-test. P values were < 0.05 (*), 0.01 (**), or <
0.001 (***).
While these results were obtained by intraperitoneal injection of picracin or DAP,
another experiment was performed to determine whether the inhibitory activity was
enhanced after local administration of either of the two compounds. For this, a mixture of
sheep erythrocytes with picracin, deacetylpicracin, or dexamethasone was given by means
of subplantar injection in the hind paw. In this experiment, however, an increase in
swelling rather than a decrease was observed in groups treated with picracin or DAP,
suggesting an irritating or toxic response for both compounds at all concentrations tested
(figure 5).




















Figure 5. Effects of picracin, deacetylpicracin (DAP), and dexamethasone on DTH-
response in mice after subplantar administration. Results are representative of two
independent experiments. Data were expressed as means ± SEM (n = 6 per group) and
statistically analyzed by the Student’s t-test. P values are < 0.01 (**) or < 0.001 (***).
To confirm the direct irritating or toxic effect of picracin or DAP, sensitized mice
were given a subplantar injection of picracin or DAP (10, 1.0, or 0.1 µg/ml), suspended in
PBS, in the absence of antigen. After 24 h, the paw swelling was measured. Picracin (10
µg/ml and 1.0 µg/ml), and to a lesser extend DAP (10 µg/ml), showed a significant
irritating effect (figure 6).




















Figure 6. Direct irritant effects of picracin and deacetylpicracin (DAP) after subplantar
administration. Data were expressed as means ± SEM (n = 5 per group) and statistically
analyzed by the Student’s t-test. P values are < 0.05 (*), < 0.01 (**), or < 0.001 (***).
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Discussion
Delayed-type hypersensitivity (DTH) is a valuable model to demonstrate cell-
mediated immune responses, which are mediated mainly by T cells. Kerckhaert et al.
(1974) showed that a single injection of cyclophosphamide (300 mg/kg) 8 h before
immunization resulted in an enhanced DTH-response 10 days after immunization, and a
decreased B-cell response during the whole experiment. Later research demonstrated the
selective inactivation of suppressor T cells or their precursors by cyclophosphamide
(Kaufmann et al., 1980, Bovbjerg et al., 1986), and the selective induction of apoptosis in
differentiating B cells as compared with T cells in vivo (Hemendinger and Bloom, 1996).
Therefore, this model was chosen to determine the effects of picracin or deacetylpicracin in
vivo, with dexamethasone serving as a positive control (Schrier et al., 1985). The
significant decrease in paw edema upon systemic administration of picracin or
deacetylpicracin suggests that these substances are immunosuppressive. However, their
effects were less prominent than the effects of dexamethasone, which is considered an anti-
inflammatory rather than an immunosuppressive drug. To determine whether local
administration would enhance the effects observed, the compounds were injected directly
within the area of inflammation. The inhibitory effects of both cucurbitacins, however,
could not be enhanced by local, subcutaneous administration. Instead, an increased
swelling was observed. Control experiments revealed a concentration-dependent direct
inflammatory response of picracin, which was significant at low concentrations (1 µg/ml
and 10 µg/ml), and a minor but significant effect of deacetylpicracin at 10 µg/ml, the
highest concentration tested.
The inflammatory and immunosuppressive effects observed for picracin and
deacetylpicracin suggest a dualistic effect of these compounds. Upon local administration,
they might induce a direct inflammatory response, while upon systemic administration
(i.p.) they might be metabolically converted into compounds that exhibit
immunosuppressive effects instead. Alternatively, the effects might be related to the
induction of T-cell apoptosis in the paw. Apoptosis is usually not associated with
inflammation, because the apoptotic bodies, which are the result of apoptosis, are ingested
by surrounding phagocytes and any leakage of their contents is thus avoided (Savill et al.,
1993). However, Uchimura et al. (1997) demonstrated that apoptotic CTL-L2 cells, co-
cultured with peritoneal exudate cells, resulted in the production of both anti-inflammatory
and pro-inflammatory cytokines. Culture supernatants induced the accumulation of
neutrophils in vivo (Uchimura et al., 1997). These findings suggest that apoptosis is
associated with leukocyte infiltration in vivo. Whether this effect is associated with edema
and inflammation remains unclear. However, the intraperitoneal administration of high
doses of picracin or deacetylpicracin, e.g. 30 and 100 mg/kg, might induce a strong influx
of leukocytes secondary to T-cell apoptosis. Leukocytes might as well be withheld from
the paw, leaving behind a reduced number of inflammatory cells to elicit a local immune
response after subcutaneous injection of antigen. A similar phenomenon has been
described before as counter-irritation, e.g. inflammation in progress at one site decreases
edema formation at a second and separate inflammatory focus (Normann et al., 1985).
In conclusion, picracin and deacetylpicracin, two cucurbitacins isolated from
Picrorhiza scrophulariiflora, which inhibit mitogen-induced proliferation of T cells, are
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potent inhibitors of IL-2 release. Furthermore, picracin potently induced apoptosis of non-
stimulated T cells, while deacetylpicracin was much less active. The induction of apoptosis
by picracin might explain its inhibitory effects on the proliferation of T cells and its
inhibition of IL-2 release. The inferior effects of deacetylpicracin in inhibiting IL-2 release
and inducing apoptosis might be due to the lower lipophilicity of deacetylpicracin. The
inactivity of deacetylpicracin and the activity of picracin to inhibit the release of IL-1β and
TNFα in LPS-stimulated monocytes upon 24-h co-incubation, suggest that these effects
might be ascribed to the induction of apoptosis as well, although further research has to
confirm any apoptosis-inducing effect on monocytes. Furthermore, picracin and
deacetylpicracin moderately inhibited delayed-type hypersensitivity responses in mice
upon intraperitoneal administration, while subplantar injection in the paw elicited a local
inflammatory response. These observations suggest the attraction of phagocytes, secondary
to T-lymphocyte apoptosis in vivo, and producing a counter-irritant effect upon
intraperitoneal administration of these compounds.
Although our findings do not favor the usefulness of picracin and deacetylpicracin in
autoimmune disorders such as rheumatoid arthritis, these compounds might be useful tools
in studying the effects of apoptosis induction in vivo. Furthermore, the effect of picracin on
T-cell proliferative disorders needs study, as well as its effect on cell arrest extended to
other cell types and relevant diseases. Picracin might serve as a lead compound for the
development of pharmacotherapeutics, effective in such diseases.
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Summarizing discussion
Natural products have been an important resource for the maintenance of life for ages.
The interest in medicinal plants has never ceased since. Even today, natural products
become increasingly important as a source of pharmacotherapeutics, either directly, e.g. in
the application of herbal drugs for the treatment of chronic diseases, or as a source of more
or less complex chemical structures are isolated, with a particular biological activity.
Instead of random screening of a large number of plant extracts, traditional systems of
medicine provide an extremely vast body of source material for the development of new
drugs (Holland, 1994). Evaluation of traditionally used medicines, keeping into account the
traditional principles that are applied in drug therapy, may supply leads towards effective
drug discovery.
Previously, based on such an approach, P. kurrooa Royle was identified as a potential
source of immunomodulating compounds (Labadie et al., 1989), and its modulatory effects
on complement activation and the production of chemiluminescence by activated
neutrophils were investigated (Simons, 1989). Because oxidative stress due to reactive
oxygen species is a major contributor to joint damage in rheumatoid arthritis (Halliwell
and Gutteridge, 1999), these data suggested the usefulness of Picrorhiza in the treatment of
this disease. This thesis deals with the further pre-clinical evaluation of the
immunomodulatory activity of Picrorhiza and the activity-guided isolation of active
constituents, in order to assess its usefulness in rheumatoid arthritis or related conditions.
Rhizomes of two Picrorhiza species happen to be available on South-Asian markets,
e.g. P. kurrooa Royle and P. scrophulariiflora Pennell (Scrophulariaceae). Both species
are known under the same local name, and used for similar purposes. Because the plant
material under investigation was obtained as a simplex, and there are no discriminative
features between the rhizomes of both species, the identity of the plant material could not
directly be determined. However, an inventory of the geographical distribution of both
Picrorhiza species provided sufficient circumstantial evidence to establish the proper
identity, as described in chapter 2. The material was obtained from Gorkha District, Nepal.
Literature review revealed that the distribution of P. kurrooa is restricted to the Western
Himalaya, from Kashmir to Kumaon, while P. scrophulariiflora is found in the Eastern
Himalaya, from Garhwal to Sikkim. This observation is a strong argument to consider the
identity of the Gorkha material to be P. scrophulariiflora. Observations by Olsen (1998)
confirm the exclusive occurrence of P. scrophulariiflora in Gorkha District of Central
Nepal. Fieldwork into Gorkha District supports this conclusion, showing the exclusive
presence of P. scrophulariiflora in this area. Although Hong categorized this species into a
separate genus and named it “Neopicrorhiza scrophulariiflora” (Hong, 1984), for reasons
of clarity, described in chapter 2, the name Picrorhiza scrophulariiflora is maintained
throughout this thesis.
Chapter 3 deals with the uses of Picrorhiza in Āyurveda, the traditional medicine of
South Asia. The applicability of a plant for the treatment of a particular disease can be
derived from generalized traditional principles, or obtained directly from traditional uses.
When using the first approach, in which the properties of Picrorhiza according to
Āyurveda were considered, it became clear that Picrorhiza increases vāta (wind), and as
such, causes or aggravates vātika disorders. Vāta plays an important role in the
development of āmavāta  (rheumatoid arthritis), although this disease is usually not
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classified among the vātika diseases, but described as a separate disease entity. Its primary
cause is not derangement of vāta, but the formation of āma (undigested food materials).
Picrorhiza has the properties of inducing digestion and removal of āma. This suggests that,
according to Āyurvedic principles, it will be useful in the prevention of āmavāta
(rheumatoid arthritis). For the treatment of established āmavāta, however, it is not
recommended, because of its vāta-enhancing activity. Regarding the inductive approach,
e.g. direct exploitation of traditional claims, references to the treatment of arthritis with
Picrorhiza as a single drug are not found in Āyurvedic literature. Upon investigating the
use of Āyurvedic preparations of Picrorhiza, a similar result was obtained. Moreover,
fieldwork in northern India and Nepal yielded thirty-three different commercially available
preparations that contain Picrorhiza, while four of them were prescribed for the treatment
of rheumatic conditions. Seventeen of the products obtained were classical Āyurvedic
preparations, while the others were proprietary products, developed by Āyurvedic
companies. However, according to the original sources, only ten of these classical
preparations contained Picrorhiza, and only one is sometimes used for the treatment of
āmavāta, although this is not indicated in the original source. Furthermore, this preparation
contains just a fraction of Picrorhiza, if any. Therefore, based on both deductive and
inductive approaches, it can be concluded that Picrorhiza does not play an important role
in the treatment of āmavāta. However, according to Āyurvedic principles, Picrorhiza
remains a potent therapy in the prevention of āmavāta (rheumatoid arthritis).
Review of the experimental literature on Picrorhiza species, as described in chapter 4,
revealed the accumulation of cucurbitacin glucosides, iridoid glucosides, phenylethanoid
glucosides, and acetophenone glucosides in the rhizomes of Picrorhiza. These compounds
have a wide range of biological activities, among which anti-inflammatory effects seem to
prevail. Hardly any information on the effects of the cucurbitacins from Picrorhiza is
available. Other cucurbitacins, however, are described to have cytotoxic and antitumor
effects, immunomodulating and adaptogenic activities. Some particular cucurbitacins are
highly toxic. As far as iridoid glucosides concerned, the effects described relate mainly to a
protection of the liver against experimentally induced damage. In contrast, phenylethanoid
glucosides exhibit anti-inflammatory effects by inhibiting pro-inflammatory responses, e.g.
by diminishing phosphodiesterase and 5-lipoxygenase activities. Acetophenones like
apocynin contribute to the anti-inflammatory effects by interfering with the formation of
reactive oxygen species and enhancing the physiological antioxidant system, which lead to
a wide range of secondary effects.
Chapter 5 describes the modulating activities of Soxhlet extracts of P.
scrophulariiflora on the classical complement pathway, the release of chemiluminescence
by neutrophil leukocytes, and the proliferation of T lymphocytes, as a reflection of
nonspecific humoral and cellular defense mechanisms, and specific cellular immune
responses. The diethyl-ether Soxhlet extract was the most anti-inflammatory of all extracts
prepared, concerning both nonspecific (complement and respiratory burst) and specific (T-
cell proliferation) immune responses. Furthermore, prolonged administration of this extract
showed inhibition of carrageenan-induced paw edema in mice. The light petroleum and
aqueous extracts were less active in inhibiting the classical complement pathway, while the
ethyl acetate and methanol extracts moderately inhibited chemiluminescence by activated
PMNs. In vivo, however, these extracts were completely inactive in the doses tested. The in
vivo anti-inflammatory activity of the diethyl-ether extract is in line with the effects
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observed in vitro for this extract. We assume that at least a part of the processes suggested
to be involved in carrageenan-induced paw edema (activation of complement;
degranulation of mast cells; release of kinins; release of reactive oxygen or nitrogen
species by activated phagocytes; arachidonic acid metabolites; and pro-inflammatory
cytokines) is subject of inhibition by P. scrophulariiflora extracts. Moderate inhibitory
activity on activated neutrophils in vitro, as shown for the diethyl ether and the ethyl-
acetate extracts, was mainly attributed to apocynin. However, apocynin did not show any
anti-inflammatory effect in the acute inflammation model, suggesting that compounds
other than apocynin are responsible for the anti-inflammatory effects observed. This effect
may be due to the presence of compounds, which inhibit activation of complement.
Alternatively, a combination of immunomodulating compounds with different mechanisms
of action might be necessary to produce anti-inflammatory activity in vivo.
Collagen-induced arthritis in mice was used as a model to determine the effects of P.
scrophulariiflora extracts on chronic inflammation. Treatment with 200 mg/kg diethyl-
ether extract or 20 mg/kg apocynin reduced the incidence of arthritis, while ethyl acetate
and methanol extracts were not active. However, neither of the samples tested,
significantly affected the severity of arthritis. These results suggest that the inhibitory
activity of the diethyl-ether extract can be attributed to apocynin. Furthermore, it seems
that the in-vitro inhibitory effects of the diethyl ether extract on complement activation,
chemiluminescence of activated PMNs, and T-cell proliferation, do not predict inhibitory
activity in collagen-induced arthritis in mice. This might be due to under-dosage, low
biological availability, an insufficient pharmacokinetic profile, or to metabolic inactivation
of active compounds in vivo. It is also possible that pathological processes, other than those
referred to and not or insufficiently inhibited by the diethyl ether extract, lead to the
development of collagen-induced arthritis in mice. The in vivo effects were not associated
with significant toxicity, as tested in mice by a semi-chronic assay involving body weight
and weights of critical lymphoid organs. Even in doses up to 100 × the intended dose of
application in humans, the extracts were devoid of significant toxicity.
Several activity-guided purification methods have been followed in order to isolate
compounds from P. scrophulariiflora that inhibit complement activation. A representative
overview of these methods is presented in chapter 6. It has become clear that in both the
light petroleum and the diethyl ether extracts several compounds are present, which
potently inhibit the classical pathway of complement activation. It seems, however, that the
respective amounts of these compounds in the extracts are rather low, making isolation and
identification very tedious and incomplete within the time span available. However, TLC
analysis suggested the presence of phytosterols in the light petroleum extract. Although
these compounds have not been demonstrated in Picrorhiza species before, phytosterols
are ubiquitous in higher plants and are described to exhibit potent complement-depleting
activity (Yamada et al., 1987, Oh et al., 1998). Furthermore, cucurbitacins may also play a
role in the interference of the diethyl-ether extract with the complement system. Huang et
al. (1998) demonstrated the presence of complement-inhibiting cucurbitacin glycosides
from Picria fel-terrae Lour. (Scrophulariaceae). Cucurbitacin glucosides are abundantly
present in Picrorhiza species (Stuppner et al., 1991; Wang et al., 1993). While cucurbitacin
glucosides might not be present in the apolar diethyl-ether extract, it is possible that their
corresponding aglucones are responsible for the activity observed.
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Chapter 7 describes the isolation of two cucurbitacins from the rhizomes of P.
scrophulariiflora, guided by inhibitory activity in a mitogen-induced human T-lymphocyte
proliferation assay. The diethyl-ether extract, which potently inhibited proliferation, was
subjected to Silica column chromatography, followed by crystallization of active fractions,
yielding deacetylpicracin. Other fractions were subjected to Sephadex LH20 column
chromatography and preparative HPLC, yielding picracin. A third active compound could
not be isolated yet. The structures of both isolated compounds were determined by EIMS,
FABMS, IR, 1H NMR, and 13C NMR spectroscopy, revealing their identity as aglycones of
known 11-deoxycucurbitacin glucosides (Laurie et al., 1985, Stuppner and Wagner, 1989).
Both compounds exhibited a potent inhibition of PHA-induced T-cell proliferation.
Because cucurbitacins are well known for their cytotoxic behavior, direct cytotoxic
properties of the two compounds were determined. Labeling the PHA-stimulated
lymphocytes after 4-day incubation with carboxyfluorescein diacetate and propidium
iodide to distinguish between viable and dead cells, showed only minor cell death (< 10 %)
for concentrations of picracin and deacetylpicracin below 60 µM. Another cytotoxicity
experiment, using the lactate dehydrogenase release assay, did not show any toxic effect up
to 50 µM for both cucurbitacins after 24 h. As these concentrations are much higher than
the IC50 values of both compounds (1 µM), it can be concluded that the inhibitory activity
of picracin and deacetylpicracin is most probably not to be ascribed to direct cytotoxic
effects.
Following the isolation of compounds that inhibit T-cell proliferation, possible
underlying mechanisms were investigated, as described in chapter 8. Since proliferation of
activated T cells is mediated by the release of IL-2 and the subsequent interaction with the
IL-2 receptor, the effects of these compounds on the release of IL-2 by activated T
lymphocytes were determined. Incubation of activated T cells with picracin or
deacetylpicracin for 24 h showed a marked inhibition of IL-2 release after 24 h, which
could not be ascribed to a direct toxic effect. Furthermore, cucurbitacin E, a cucurbitacin
known to inhibit the proliferation of endothelial cells (Duncan and Duncan, 1997),
inhibited IL-2 release as well. However, fluorescence microscopical analysis following
staining of cells with CFDA and PI demonstrated that in this case a direct cytotoxic effect
might be involved. These data explain the antiproliferative activity of picracin and
cucurbitacin, since IL-2 is responsible for signaling T-cell proliferation (Smith, 1988).
The interference of picracin and deacetylpicracin with IL-2 release by activated T
lymphocytes could be the result of a specific interaction with signal transduction pathways
leading to the release of IL-2, or due to the induction of apoptosis, which renders the T cell
incapable of releasing IL-2. To assess the apoptotic effect of picracin and deacetylpicracin,
PBL were stained with FITC-conjugated annexin V and propidium iodine. Cytometric
analysis showed a significant induction of apoptosis by picracin, while deacetylpicracin
was about three times less effective, and not significantly different from untreated cells
(chapter 8). The inferior effects observed for deacetylpicracin in pro-inflammatory
cytokine release and the induction of apoptosis may be due to its lower lipophilicity, which
might result in a less pronounced interaction with cell membranes, and a delayed capacity
to induce apoptosis.
In addition to the effects on T lymphocytes, the effects of picracin and
deacetylpicracin on the release of the pro-inflammatory cytokines IL-1β and TNFα by
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activated monocytes was investigated. Incubation of human monocytes with picracin for
24 h inhibited the release of IL-1β and TNFα, while deacetylpicracin was not active. The
inhibitory activity of cucurbitacin E was found to be in the same order of magnitude as that
of picracin. As both compounds differ only in the presence of carbonyl functionalities at
C3 and C11, and a C1-2 double bond, the acetyl functionality in the side chain might be
essential in the inhibiting of IL-1β and TNFα release.
Delayed-type hypersensitivity, a valuable model to demonstrate cell-mediated immune
responses, was used to determine the effects of picracin and deacetylpicracin in vivo. Both
picracin and deacetylpicracin significantly inhibited paw edema, at doses of 100 mg/kg and
30 mg/kg, respectively, upon intraperitoneal administration. To determine whether local
administration would enhance the effects observed, the compounds were injected directly
within the area of inflammation. The inhibitory effects of both cucurbitacins, however,
could not be enhanced by local, subcutaneous administration. Instead, an increased
swelling being observed. Control experiments revealed a concentration-dependent direct
inflammatory response, which was significant even at low concentrations.
The inflammatory and immunosuppressive effects observed for picracin and
deacetylpicracin suggest a dualistic effect of these compounds. Upon local administration,
they might induce a direct inflammatory response, while upon systemic administration
(i.p.) they might be metabolically converted into compounds that exhibit
immunosuppressive effects instead. Alternatively, the effects might be due to the induction
of T-cell apoptosis in the paw. Although apoptosis is usually not associated with
inflammation, because the apoptotic cells are ingested by surrounding phagocytes before
any leakage of their contents can occur, they can induce the production of cytokines by
peritoneal exudate cells in vitro, which was related to the accumulation of neutrophils in
vivo (Uchimura et al., 1997). These findings suggest that apoptosis is associated with
leukocyte infiltration in vivo. Whether this effect is associated with edema and
inflammation remains unclear. However, the intraperitoneal administration of high doses
of picracin or deacetylpicracin might induce a strong influx of leukocytes secondary to T-
cell apoptosis. Leukocytes might as well be withheld from the paw, leaving behind a
reduced number of inflammatory cells to elicit a local immune response after subcutaneous
injection of antigen.
Summarizing, the diethyl-ether Soxhlet extract of dried rhizomes of Picrorhiza
scrophulariiflora potently inhibited the classical complement pathway, the release of
chemiluminescence by activated neutrophils, and the mitogen-induced proliferation of T
lymphocytes. Prolonged oral administration of this extract inhibited carrageenan-induced
paw edema in mice and delayed the incidence of collagen-induced arthritis. The activity in
acute inflammation may involve compounds interfering with the classical complement
pathway, while the activity in chronic inflammation could be ascribed to apocynin.
Activity-guided isolation revealed the presence of several complement-modulating
compounds, although these compounds were not isolated yet. Furthermore, based on
activity in the T-cell proliferation assay, two cucurbitacins were isolated from this extract
and their structures were elucidated. In addition to the inhibitory effects of these
compounds on the proliferation of T lymphocytes, they also inhibited the release of IL-2.
Moreover, picracin, but not deacetylpicracin, inhibited the release of IL-1β and TNFα by
activated monocytes. These effects might be due to the induction of apoptosis, which was
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demonstrated for T cells after incubation with picracin. Induction of apoptosis might play a
role in the local immunostimulatory effects of picracin and deacetylpicracin in vivo, while
a similar effect might be responsible for the inhibitory effects on delayed type
hypersensitivity, mediated via a counter-irritation phenomenon. Alternatively, upon local
administration these compounds might induce a direct inflammatory response, while upon
systemic administration (i.p.) they might be metabolically converted into compounds that
exhibit immunosuppressive effects.
In conclusion, several compounds play a role in immunomodulatory effects induced
by Picrorhiza extracts. Picracin and deacetylpicracin induce a local immune response upon
local administration, while they tend to decrease a local inflammatory response after
systemic (i.p.) administration. Although the latter results are promising with regard to the
anti-inflammatory activity of Picrorhiza, it cannot be excluded that these compounds
enhance local inflammation and for example aggravate rheumatoid arthritis. Testing of
picracin and deacetylpicracin in experimentally induced arthritis should be performed in
order to evaluate such effects. Both compounds are present in the diethyl-ether extract,
which decreased the onset of arthritis in mice. However, apocynin was shown to exhibit
similar effects, therefore, this compound might be responsible for the effects observed for
the diethyl-ether extract in collagen-induced arthritis. Neither the diethyl-ether extract, nor
apocynin decreased the severity of joint inflammation in the dosages used. These findings
are in agreement with the contraindication of Picrorhiza for the treatment of rheumatoid
arthritis, both according to contemporary use and according to Āyurvedic principles.
However, the experimental results as well as the conclusions drawn from the Āyurvedic
properties of Picrorhiza suggest that it can play an important role in the prevention of
rheumatoid arthritis.
Perspectives
A possible application of the cellular effects induced by picracin might be in the
interference with the cell skeleton. Several cucurbitacins (cucurbitacin D, I, E, and 2-
methoxy-cucurbitacin E) are shown to induce morphological changes to Ehrlich ascites
tumor cells at low concentrations. Only at higher concentrations, viability, respiration, and
permeability of these cells were affected, without an increase of the morphological
changes. Similar changes were observed in vivo, 1 hour after i.p. injection of cucurbitacin
D into ascites-bearing mice. In samples drawn 24 h after injection, however, no deformed
or necrotized tumor cells were found (Gitter et al., 1961).
These observations are confirmed by Duncan et al. (1996), who demonstrated
cucurbitacin E-induced cell growth inhibition of prostrate carcinoma cells, even after drug
removal. Furthermore, exposure to cucurbitacin E led to the development of
morphologically abnormal, multinucleated cells, associated with a change in vimentin
distribution. Cucurbitacin E was shown to disrupt the filamentous (F)-actin cytoskeleton,
which correlated with its antiproliferative effect (Duncan et al., 1996). Moreover,
cucurbitacin E interfered with the actin cytoskeleton of human endothelial cells, showing
preferential sequestration in proliferating cells (Duncan and Duncan, 1997). The actin
cytoskeleton has been implicated as critical intermediates in several signal transduction
pathways controlling cell division (Aderem, 1992, Luna and Hitt, 1992). TCR-mediated
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stimulation of T cells leads to the organization of Caps, assemblies of receptors and
signaling molecules at the surface of T lymphocytes following activation (Monks et al.,
1998, Penninger and Crabtree, 1999). The forces driving the formation of these structures
require actin polymerization in T cells (Wülfing et al., 1998). This cytoskeleton
reorganization plays an important role in downstream signal transduction (Valitutti et al.,
1995).
Although interference of picracin and deacetylpicracin with the cytoskeleton of
activated T cells has not been reported, the similarity of picracin and cucurbitacin E as far
as structure and biological effects are concerned could indicate a similar mechanism in
blocking signal transduction pathways. Furthermore, although the induction of T-cell
apoptosis by cucurbitacin E has not been demonstrated so far, the effects of cucurbitacin E
on the cytoskeleton, in association with its antiproliferative effect towards tumor cells and
proliferating endothelial cells, might be explained by the induction of apoptosis in these
cells. A similar mechanism might explain the induction of apoptosis by picracin and
deacetylpicracin upon exposure to activated T cells.
Several compounds, mainly derived from natural products, are known to interfere with
the cytoskeleton, some of them being very effective in cancer chemotherapy (Jordan and
Wilson, 1998). Cytochalasins are fungal metabolites and among the best-studied agents
acting on actin-filament organization and the subsequent effect on cell functioning
(Cooper, 1987). Cytochalasin D abrogates actin polymerization, Cap formation, and
subsequent downstream signal transduction leading to IL-2 transcription upon antigen
receptor activation of T lymphocytes (Holsinger et al., 1998). Furthermore, cytochalasin D
induces apoptosis of CD4+ T cells, which correlates with its affinity for the polymerization
ends of actin filaments. Moreover, the cytochalasin-D-induced cytoskeletal disruption was
associated with the up-regulation of caspase-3 protease activity and an increased
accessibility of active caspase-3 to its substrate (Suria et al., 1999). Caspases are proteases,
involved in the intracellular proteolytic machinery ultimately leading to apoptosis. They
inactivate proteins that protect living cells from apoptosis, disassemble cell structures, and
as such contribute to chromatin condensation, and inactivate proteins involved in
cytoskeletal regulation (Thornberry and Lazebnik, 1998).
Although several gaps have yet to be filled in, the mechanism of picracin-mediated
cell arrest might be of similar nature. Its effects on T lymphocytes might be due to a
disturbance of the cytoskeletal organization, leading to a downstream activation of
caspases, and a subsequent induction of apoptosis. Future research in order to substantiate
this hypothesis should be focusing on the effect of picracin on the actin-cytoskeleton and
subsequent effects on caspase activity. Furthermore, the effect of picracin on T-cell
proliferative disorders needs study, as well as its effect on cell viability extended to other
cell types and relevant diseases. Finally, picracin and deacetylpicracin may serve as lead
compounds for the development of novel anticancer drugs.
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DE diethyl ether (extract)
dex dexamethasone





EA ethyl acetate (extract)
ED50 dose at 50 % effect
EGTA ethylene glycol-bis-(β-aminoethyl ether)
=AFE2 $'$,./5*#)4&(,.F4(""#"&$,./54$./6
ELISA enzyme-linked immunosorbent assay
EtOH ethanol (extract)
D!iFE2 ;(".#(.54#<54<(/+4$*.F4(""#"&$,./54$./6
FACScan fluorescence activated cell scan
F-actin filamentous actin
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HBSS Hank’s buffered salt solution
j=PYk_ -$.$/5*7,'$(/#,5//$'(.)5*
HETE hydroperoxy eicosatetraenoic acid
HIF-1 hypoxia inducible factor-1
HPLC high performance liquid chromatography
HPS human pooled serum
i.p. intraperitoneally
i.v. intravenously
IC50 concentration at 50 % inhibition
ICAM-1 intercellular adhesion molecule-1







LD50 dose at 50 % lethality
LDH lactate dehydrogenase
LFA lymphocyte function associated molecule
LPS lipopolysaccharide
LTB leukotriene
MAC major attack complex
MASP mannose-binding lectin-associated serine protease
MBL mannose-binding lectin
MCP monocyte chemoattractant protein
Me methanol (extract)





NAD β-nicotinamide adenine dinucleotide
NADPH nicotinamide adenine dinucleotide phosphate
nd not detectable
*) *)+N*(".-N*(
NMR nuclear magnetic resonance spectrometry
NSAID non-steroid anti-inflammatory drug
p.o. per os; orally
PAF platelet activating factor
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PBMC peripheral blood mononuclear cells
PBS phosphate-buffered saline






PKC protein kinase C











SDS sodium dodecyl sulphate
SEM standard error of mean
sGPT serum glutamic-pyruvic transaminase
2Z# dN')>/N4(*)>-(b`7





Th1 cell T-helper-1 cell
TLC thin-layer chromatography
TNFα tumor necrosis factor α
TXA2 thromboxane A2
v/v volume per volume
VBS veronal-buffered saline
VEGF vascular endothelial growth factor
9) 9)4N*(".-N*(
w/w weight per weight
l_ 65>(/(.*N3(/(
Appendices |  147
Samenvatting .
Het gebruik van medicinale planten ter behoud en verhoging van de kwaliteit van
leven is eeuwenoud en nog steeds actueel. De laatste jaren is er zelfs een sterke toename
waar te nemen van de interesse voor en het gebruik van natuurlijke produkten in de
gezondheidszorg. Dit gebeurt aan de ene kant door het rechtstreeks toepassen van kruiden
of afgeleide bereidingen, bijvoorbeeld bij de behandeling van chronische aandoeningen;
aan de andere kant dienen planten als grondstof voor de isolatie van biologisch actieve
verbindingen. Deze verbindingen kunnen worden ontsloten door het willekeurig
onderzoeken van grote aantallen planten extracten, maar ook een voorselectie worden
gemaakt op grond van traditionele kennis van het gebruik van kruiden. De beoordeling van
traditioneel gebruikte kruidenpreparaten, waarbij recht wordt gedaan aan de traditionele
principes van gezondheid en ziekte, kan leiden tot het ontwikkelen van nieuwe
geneesmiddelen.
Voorheen werd via een dergelijke benadering Picrorhiza kurrooa Royle (letterlijk:
“Bitterwortel”) geselecteerd als een mogelijk interessante middel voor
immuunmodulerende verbindingen. Resultaten van onderzoek naar de effecten van deze
plant op het complement systeem en op de vorming van zuurstof radicalen door
geactiveerde witte bloedcellen (leukocyten) suggereerde een mogelijke toepassing bij
reumatoïde gewrichtsontsteking. Dit proefschrift handelt over aanvullend onderzoek naar
de immuun modulerende eigenschappen van Picrorhiza en de isolatie van biologisch
actieve verbindingen, om een beter beeld te krijgen van de toepasbaarheid van deze plant
in chronische gewrichtsontsteking.
Wortelstokken van twee verschillende Picrorhiza soorten zijn verkrijgbaar op Zuid-
Aziatische kruidenmarkten, te weten P. kurrooa Royle en P. scrophulariiflora Pennell. Er
wordt geen onderscheid gemaakt tussen de wortelstokken van beide soorten. Aangezien het
plantenmateriaal dat voor dit onderzoek werd gebruikt bestond uit gedroogde
wortelstokken, en er geen methoden bekend zijn om wortelstokken van beide soorten te
onderscheiden, kon de identiteit van het plantenmateriaal niet rechtsreeks worden
vastgesteld. Echter, een inventarisatie van de geografische verspreiding van beide soorten,
beschreven in hoofdstuk 2, leverde voldoende aanwijzingen om de identiteit van het
gebruikte plantenmateriaal vast te kunnen stellen. Het materiaal werd verkregen uit het
Gorkha district in Nepal. Een inventarisatie van de locaties waar Picrorhiza soorten zijn
gevonden wees uit dat de verspreiding van P. kurrooa zich beperkt tot de Westelijke
Himalaya, terwijl P. scrophulariiflora voorkomt in de Oostelijke Himalaya. Voorts bleek
uit onderzoek dat in het Gorkha district slechts P. scrophulariiflora voorkomt, hetgeen
werd bevestigd door veldwerk in dit gebied. Op basis van deze informatie werd
verondersteld dat het gebruikte plantenmateriaal vastgesteld als P. scrophulariiflora.
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Hoewel deze soort in 1984 werd ondergebracht in een nieuw geslacht, namelijk
Neopicrorhiza, is het gebruik van de synoniem Picrorhiza scrophulariiflora gehandhaafd
in dit proefschrift. De argumenten die ten grondslag liggen aan deze keuze worden
beschreven in hoofdstuk 2.
Hoofdstuk 3 beschrijft het gebruik van Picrorhiza in de Āyurveda, de traditionele
geneeskunde van Zuid Azië. De toepasbaarheid een medicinale plant voor de behandeling
van een bepaalde aandoening kan worden afgeleid aan de hand van gegeneraliseerde
traditionele principes, of rechtstreeks worden ontleend aan het traditionele gebruik.
Wanneer voor de eerste benadering wordt gekozen, waarbij de Āyurvedische
eigenschappen van Picrorhiza in aanmerking worden genomen, wordt het duidelijk dat
deze plant de vāta (vgl. wind) verhoogd en als zodanig ziekten die zijn veroorzaakt door
vāta kunnen verergeren. Hoewel vāta een belangrijke rol speelt in het ontstaan van
āmavāta (reumatoïde artritis), is dit toch niet de hoofdoorzaak. Deze wordt veeleer
gevormd door het verschijnsel āma (onvolledig verteerde nutriënten). Picrorhiza heeft als
eigenschappen het bevorderen van de spijsvertering en het verwijderen van āma. Dit
suggereert dat Picrorhiza, volgens de Āyurvedische principes, een belangrijke rol kan
spelen in het voorkómen van reumatoïde gewrichtsontsteking. Voor de behandeling
hiervan wordt het echter niet aangeraden vanwege het stimulerende effect of vāta.
Eenzelfde conclusie werd getrokken na onderzoek van de toepassing van Āyurvedische
bereidingen van Picrorhiza. Verwijzingen uit de klassieke literatuur naar het gebruik van
Picrorhiza bij gewrichtsontsteking werden niet gevonden. Bovendien bleek uit
veldonderzoek in Noord India en Nepal dat complexe bereidingen met een substantiële
hoeveelheid Picrorhiza niet gebruikt worden voor de behandeling van chronische
gewrichtsontsteking.
Uit onderzoek van Picrorhiza soorten, zoals beschreven in hoofdstuk 4, blijkt dat met
name cucurbitacin glucosiden, iridoid glucosiden, phenylethanoid glucosiden en
acetophenon glucosiden worden geaccumuleerd in de wortelstokken van Picrorhiza
soorten. Deze componenten hebben een wijd uiteenlopende biologische activiteit, waarin
echter ontstekingsremmende effecten de overhand hebben. Hoewel vrijwel geen informatie
beschikbaar is over de biologische activiteit van cucurbitacinen uit Picrorhiza, worden van
andere vergelijkbare verbindingen cytotoxische, antitumor, immuun modulerende en
adaptogene effecten beschreven. Tevens is bekend dat sommige cucurbitacinen sterk giftig
zijn. De effecten die beschreven zijn voor iridoid glucosiden houden meestal verband met
de bescherming van de lever tegen experimenteel geïnduceerde schade. De werking van
phenylethanoid glucosiden wordt meestal in verband gebracht met de remming van
enzymen die een rol spelen bij het ontstaan van ontstekingsreacties, zoals
phosphodiesterase en 5-lipoxygenase. Acetophenonen zoals apocynin dragen bij aan de
ontstekingsremmende werking door de remming van de vorming van zuurstofradicalen en
de verhoging van het cellulaire antioxidant systeem.
 Hoofdstuk 5 beschrijft het onderzoek naar de modulerende eigenschappen van
extracten van P. scrophulariiflora op de klassieke route van het complement systeem, de
produktie van chemiluminescentie door leukocyten en de proliferatie van T lymfocyten. De
onderzochte processen weerspiegelen aspecifieke humorale en cellulaire
verdedigingsmechanismen en tevens specifieke immuunreacties. Van de geteste extracten
vertoonde het diethylether Soxhlet extract de sterkste effecten, zowel in aspecifieke als
specifieke immuunprocessen. Bovendien vertoonde dit extract een remming van
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carrageenan-geïnduceerde pootzwelling in muizen na meerdere toedieningen. De
petroleumether en water extracten vertoonden minder sterke remmende effecten op de
klassieke route van het complement systeem, terwijl de ethylacetaat en methanol extracten
de chemiluminescentie van leukocyten matig remden. Deze extracten vertoonden echter
geen remmend effect op carrageenan-geïnduceerde pootzwelling in de onderzochte
doseringen. De remming van chemiluminescentie door de diethylether en ethylacetaat
extracten kan voor een groot deel worden toegeschreven aan apocynin. Echter, apocynin
vertoonde geen remmend effect in bovengenoemd model, hetgeen suggereert dat andere
stoffen verantwoordelijk zijn voor het ontstekingsremmende effect van het diethylether
extract. Het is mogelijk dat verbindingen die het complement systeem remmen hiervoor
verantwoordelijk zijn. Ook is het mogelijk dat een combinatie van verbindingen met een
verschillende werking nodig is om een onstekingsremmend effect in vivo te verkrijgen.
Kraakbeen geïnduceerde gewrichtsontsteking in muizen werd gebruikt als model om
een beeld te krijgen van de effecten van P. scrophulariiflora extracten op chronische
ontsteking. De behandeling met 200 mg/kg diethylether extract of 20 mg/kg apocynin
vertraagde de ontwikkeling van gewrichtsontsteking, hoewel geen van de geteste monsters
de ernst van de ontsteking verminderden. Deze resultaten suggereren dat apocynin
verantwoordelijk is voor de effecten van het diethylether extract op chronische
gewrichtsontsteking. Bovendien kan gesteld worden dat de remming van het diethylether
extract op het complement systeem, de chemiluminescentie en T cel proliferatie geen
voorspellende waarde hebben voor de remming van kraakbeen geïnduceerde
gewrichtsontsteking in muizen onder de onderzochte omstandigheden. De oorzaak hiervan
kan liggen in een te lage dosering, een slechte biologische beschikbaarheid, een ongunstig
farmacokinetisch profiel, of metabolische inactivering van werkzame componenten in vivo.
Het is ook mogelijk dat pathologische processen een rol spelen in het ontstaan van
chronische gewrichtsontsteking die niet zijn onderzocht of die onvoldoende worden
geremd door het diethylether extract. De in vivo effecten gingen niet gepaard met
belangrijke toxische effecten, zoals bleek uit de analyse van belangrijke immunologische
organen van muizen die gedurende 3 of 6 weken extracten van P. scrophulariiflora kregen
toegediend.
Verschillende methoden zijn gebruikt om op geleide van activiteit stoffen te isoleren
uit P. scrophulariiflora die interfereren met de klassieke route van het complement
systeem remmen. Een representatief overzicht van enkele methoden is weergeven in
hoofdstuk 6. Gedurende het onderzoek werd duidelijk dat zowel in het petroleumether als
het diethylether extract meerdere componenten aanwezig zijn die een effect hebben op
componenten van het complementsysteem. Het gehalte aan actieve verbindingen bleek
echter zeer laag wat isolatie en structuuropheldering onmogelijk maakte binnen het
beschikbare tijdsbestek. DLC analyse suggereerde echter de aanwezigheid van fytosterolen
in het petroleumether extract. Hoewel deze verbindingen niet eerder zijn aangetoond in
Picrorhiza soorten, komen fytosterolen algemeen voor in hogere planten en is hun
remmende werking op het complement systeem beschreven.
Hoofdstuk 7 beschrijft de isolatie van 2 cucurbitacinen uit de wortelstokken van P.
scrophulariiflora op geleide van groeiremming van humane T lymfocyten. Het
diethylether extract, dat een sterke remming vertoonde van celproliferatie, werd gescheiden
met behulp van Silica kolomchromatografie. Uit actieve fracties werd door kristallisatie
een zuivere actieve verbinding verkregen, deacetylpicracin. Andere actieve fracties werden
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vervolgens gescheiden met behulp van Sephadex kolomchromatografie, gevolgd door
HPLC, waardoor een tweede zuivere actieve verbinding werd verkregen, picracin. Een
derde actieve verbinding kon nog niet worden geïsoleerd. De structuur van beide
verbindingen werd opgehelderd door middel van meerdere massaspectrometrische en
NMR spectroscopische methoden. Beide componenten vertoonden een sterke remming van
T cel proliferatie. Nader onderzoek toonde aan dat deze effecten niet het gevolg waren van
direct toxische stoffen.
Mogelijke mechanismen werden onderzocht die aanleiding geven tot de waargenomen
effecten. Aangezien bij de proliferatie van T lymfocyten interleukine 2 (IL-2) een
belangrijke rol speelt, werd het effect van de geïsoleerde stoffen op de afgifte van IL-2
onderzocht. Incubatie van geactiveerde T cellen met picracin of deacetylpicracin vertoonde
een duidelijke remming van IL-2 afgifte. Dit effect kon eveneens niet worden
toegeschreven aan een direct cytotoxisch effect. Vervolgens werd onderzocht of de
remming van IL-2 afgifte het gevolg was van apoptose, ofwel geprogrammeerde celdood.
Flow cytometrische analyse van gemerkte cellen toonden aan dat picracin apoptose
induceerde in T lymfocyten, terwijl deacetylpicracin niet significant werkzaam was.
Bovendien bleek dat beide verbindingen een remmende werking hadden op de afgifte van
de ontstekingsmediatoren IL-1 en TNFα door geactiveerde monocyten. Deze stoffen
spelen een belangrijke rol in het ontstaan van chronische ontstekingen.
Beide verbindingen werden onderzocht in een diermodel voor vertraagd type
overgevoeligheid, een model voor onderzoek naar cellulaire immuunreacties. Zowel
picracin als deacetylpicracin vertoonden remming van de ontsteking na intraperitoneale
toediening. Lokale toediening veroorzaakte echter toename van de ontsteking. Controle
experimenten toonden aan dat met name picracin en in mindere mate deacetylpicracin een
dosis afhankelijke onstekingsreactie induceren in lage doseringen. Deze resultaten
suggereren een dualistisch effect van picracin en deacetylpicracin. Bij toediening in de
poot vertonen ze een plaatselijke immuunreactie, terwijl het mogelijk is dat ze na
systemische (i.p.) toediening worden omgezet in metabolieten die systemisch juist een
ontstekingsremmend effect hebben. Het is ook mogelijk dat de plaats van toediening
relevant is voor het waargenomen effect: wanneer er in de buikholte een depletie van
immuuncellen ontstaat als gevolg van apoptose, is het mogelijk dat vervolgens op een
andere plaats minder cellen beschikbaar zijn wanneer ter plekke een immuunreactie wordt
opgewekt.
Samengevat, het diethylether Soxhlet extract van gedroogde wortelstokken van
Picrorhiza scrophulariiflora een remmende werking heeft op de klassieke route van het
complement systeem, de afgifte van zuurstofradicalen of afgeleide verbindingen en de
proliferatie van T lymfocyten. Meervoudige toediening van dit extract aan muizen waarin
een acute lokale ontsteking was opgewekt resulteerde in een vermindering van de zwelling.
Bovendien vertraagde het extract de ontwikkeling van gewrichtsontsteking in muizen,
hoewel de ernst van de ontsteking niet werd beïnvloed. Activiteitsgeleide isolatie van het
diethylether extract resulteerde in 2 zuivere verbindingen die een remmend effect
vertoonden op de proliferatie van geactiveerde T lymfocyten. Beide verbindingen remden
de afgifte van IL-2 door deze cellen, en de afgifte van IL-1 en TNFα door geactiveerde
monocyten. Deze effecten zijn vermoedelijk het gevolg van het induceren van apoptose,
wat werd aangetoond door T lymfocyten te incuberen met picracin. De inductie van
apoptose speelt mogelijk ook een rol in de immuunmodulerende effecten in vivo.
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DE diethyl ether (extract)
dex dexamethasone





EA ethyl acetate (extract)
ED50 dose at 50 % effect
EGTA ethylene glycol-bis-(β-aminoethyl ether)
=AFE2 $'$,./5*#)4&(,.F4(""#"&$,./54$./6
ELISA enzyme-linked immunosorbent assay
EtOH ethanol (extract)
D!iFE2 ;(".#(.54#<54<(/+4$*.F4(""#"&$,./54$./6
FACScan fluorescence activated cell scan
F-actin filamentous actin
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HBSS Hank’s buffered salt solution
j=PYk_ -$.$/5*7,'$(/#,5//$'(.)5*
HETE hydroperoxy eicosatetraenoic acid
HIF-1 hypoxia inducible factor-1
HPLC high performance liquid chromatography
HPS human pooled serum
i.p. intraperitoneally
i.v. intravenously
IC50 concentration at 50 % inhibition
ICAM-1 intercellular adhesion molecule-1







LD50 dose at 50 % lethality
LDH lactate dehydrogenase
LFA lymphocyte function associated molecule
LPS lipopolysaccharide
LTB leukotriene
MAC major attack complex
MASP mannose-binding lectin-associated serine protease
MBL mannose-binding lectin
MCP monocyte chemoattractant protein
Me methanol (extract)





NAD β-nicotinamide adenine dinucleotide
NADPH nicotinamide adenine dinucleotide phosphate
nd not detectable
*) *)+N*(".-N*(
NMR nuclear magnetic resonance spectrometry
NSAID non-steroid anti-inflammatory drug
p.o. per os; orally
PAF platelet activating factor
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PBMC peripheral blood mononuclear cells
PBS phosphate-buffered saline






PKC protein kinase C











SDS sodium dodecyl sulphate
SEM standard error of mean
sGPT serum glutamic-pyruvic transaminase
2Z# dN')>/N4(*)>-(b`7





Th1 cell T-helper-1 cell
TLC thin-layer chromatography
TNFα tumor necrosis factor α
TXA2 thromboxane A2
v/v volume per volume
VBS veronal-buffered saline
VEGF vascular endothelial growth factor
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w/w weight per weight
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Samenvatting .
Het gebruik van medicinale planten ter behoud en verhoging van de kwaliteit van
leven is eeuwenoud en nog steeds actueel. De laatste jaren is er zelfs een sterke toename
waar te nemen van de interesse voor en het gebruik van natuurlijke produkten in de
gezondheidszorg. Dit gebeurt aan de ene kant door het rechtstreeks toepassen van kruiden
of afgeleide bereidingen, bijvoorbeeld bij de behandeling van chronische aandoeningen;
aan de andere kant dienen planten als grondstof voor de isolatie van biologisch actieve
verbindingen. Deze verbindingen kunnen worden ontsloten door het willekeurig
onderzoeken van grote aantallen planten extracten, maar ook een voorselectie worden
gemaakt op grond van traditionele kennis van het gebruik van kruiden. De beoordeling van
traditioneel gebruikte kruidenpreparaten, waarbij recht wordt gedaan aan de traditionele
principes van gezondheid en ziekte, kan leiden tot het ontwikkelen van nieuwe
geneesmiddelen.
Voorheen werd via een dergelijke benadering Picrorhiza kurrooa Royle (letterlijk:
“Bitterwortel”) geselecteerd als een mogelijk interessante middel voor
immuunmodulerende verbindingen. Resultaten van onderzoek naar de effecten van deze
plant op het complement systeem en op de vorming van zuurstof radicalen door
geactiveerde witte bloedcellen (leukocyten) suggereerde een mogelijke toepassing bij
reumatoïde gewrichtsontsteking. Dit proefschrift handelt over aanvullend onderzoek naar
de immuun modulerende eigenschappen van Picrorhiza en de isolatie van biologisch
actieve verbindingen, om een beter beeld te krijgen van de toepasbaarheid van deze plant
in chronische gewrichtsontsteking.
Wortelstokken van twee verschillende Picrorhiza soorten zijn verkrijgbaar op Zuid-
Aziatische kruidenmarkten, te weten P. kurrooa Royle en P. scrophulariiflora Pennell. Er
wordt geen onderscheid gemaakt tussen de wortelstokken van beide soorten. Aangezien het
plantenmateriaal dat voor dit onderzoek werd gebruikt bestond uit gedroogde
wortelstokken, en er geen methoden bekend zijn om wortelstokken van beide soorten te
onderscheiden, kon de identiteit van het plantenmateriaal niet rechtsreeks worden
vastgesteld. Echter, een inventarisatie van de geografische verspreiding van beide soorten,
beschreven in hoofdstuk 2, leverde voldoende aanwijzingen om de identiteit van het
gebruikte plantenmateriaal vast te kunnen stellen. Het materiaal werd verkregen uit het
Gorkha district in Nepal. Een inventarisatie van de locaties waar Picrorhiza soorten zijn
gevonden wees uit dat de verspreiding van P. kurrooa zich beperkt tot de Westelijke
Himalaya, terwijl P. scrophulariiflora voorkomt in de Oostelijke Himalaya. Voorts bleek
uit onderzoek dat in het Gorkha district slechts P. scrophulariiflora voorkomt, hetgeen
werd bevestigd door veldwerk in dit gebied. Op basis van deze informatie werd
verondersteld dat het gebruikte plantenmateriaal vastgesteld als P. scrophulariiflora.
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Hoewel deze soort in 1984 werd ondergebracht in een nieuw geslacht, namelijk
Neopicrorhiza, is het gebruik van de synoniem Picrorhiza scrophulariiflora gehandhaafd
in dit proefschrift. De argumenten die ten grondslag liggen aan deze keuze worden
beschreven in hoofdstuk 2.
Hoofdstuk 3 beschrijft het gebruik van Picrorhiza in de Āyurveda, de traditionele
geneeskunde van Zuid Azië. De toepasbaarheid een medicinale plant voor de behandeling
van een bepaalde aandoening kan worden afgeleid aan de hand van gegeneraliseerde
traditionele principes, of rechtstreeks worden ontleend aan het traditionele gebruik.
Wanneer voor de eerste benadering wordt gekozen, waarbij de Āyurvedische
eigenschappen van Picrorhiza in aanmerking worden genomen, wordt het duidelijk dat
deze plant de vāta (vgl. wind) verhoogd en als zodanig ziekten die zijn veroorzaakt door
vāta kunnen verergeren. Hoewel vāta een belangrijke rol speelt in het ontstaan van
āmavāta (reumatoïde artritis), is dit toch niet de hoofdoorzaak. Deze wordt veeleer
gevormd door het verschijnsel āma (onvolledig verteerde nutriënten). Picrorhiza heeft als
eigenschappen het bevorderen van de spijsvertering en het verwijderen van āma. Dit
suggereert dat Picrorhiza, volgens de Āyurvedische principes, een belangrijke rol kan
spelen in het voorkómen van reumatoïde gewrichtsontsteking. Voor de behandeling
hiervan wordt het echter niet aangeraden vanwege het stimulerende effect of vāta.
Eenzelfde conclusie werd getrokken na onderzoek van de toepassing van Āyurvedische
bereidingen van Picrorhiza. Verwijzingen uit de klassieke literatuur naar het gebruik van
Picrorhiza bij gewrichtsontsteking werden niet gevonden. Bovendien bleek uit
veldonderzoek in Noord India en Nepal dat complexe bereidingen met een substantiële
hoeveelheid Picrorhiza niet gebruikt worden voor de behandeling van chronische
gewrichtsontsteking.
Uit onderzoek van Picrorhiza soorten, zoals beschreven in hoofdstuk 4, blijkt dat met
name cucurbitacin glucosiden, iridoid glucosiden, phenylethanoid glucosiden en
acetophenon glucosiden worden geaccumuleerd in de wortelstokken van Picrorhiza
soorten. Deze componenten hebben een wijd uiteenlopende biologische activiteit, waarin
echter ontstekingsremmende effecten de overhand hebben. Hoewel vrijwel geen informatie
beschikbaar is over de biologische activiteit van cucurbitacinen uit Picrorhiza, worden van
andere vergelijkbare verbindingen cytotoxische, antitumor, immuun modulerende en
adaptogene effecten beschreven. Tevens is bekend dat sommige cucurbitacinen sterk giftig
zijn. De effecten die beschreven zijn voor iridoid glucosiden houden meestal verband met
de bescherming van de lever tegen experimenteel geïnduceerde schade. De werking van
phenylethanoid glucosiden wordt meestal in verband gebracht met de remming van
enzymen die een rol spelen bij het ontstaan van ontstekingsreacties, zoals
phosphodiesterase en 5-lipoxygenase. Acetophenonen zoals apocynin dragen bij aan de
ontstekingsremmende werking door de remming van de vorming van zuurstofradicalen en
de verhoging van het cellulaire antioxidant systeem.
 Hoofdstuk 5 beschrijft het onderzoek naar de modulerende eigenschappen van
extracten van P. scrophulariiflora op de klassieke route van het complement systeem, de
produktie van chemiluminescentie door leukocyten en de proliferatie van T lymfocyten. De
onderzochte processen weerspiegelen aspecifieke humorale en cellulaire
verdedigingsmechanismen en tevens specifieke immuunreacties. Van de geteste extracten
vertoonde het diethylether Soxhlet extract de sterkste effecten, zowel in aspecifieke als
specifieke immuunprocessen. Bovendien vertoonde dit extract een remming van
Appendices |  149
carrageenan-geïnduceerde pootzwelling in muizen na meerdere toedieningen. De
petroleumether en water extracten vertoonden minder sterke remmende effecten op de
klassieke route van het complement systeem, terwijl de ethylacetaat en methanol extracten
de chemiluminescentie van leukocyten matig remden. Deze extracten vertoonden echter
geen remmend effect op carrageenan-geïnduceerde pootzwelling in de onderzochte
doseringen. De remming van chemiluminescentie door de diethylether en ethylacetaat
extracten kan voor een groot deel worden toegeschreven aan apocynin. Echter, apocynin
vertoonde geen remmend effect in bovengenoemd model, hetgeen suggereert dat andere
stoffen verantwoordelijk zijn voor het ontstekingsremmende effect van het diethylether
extract. Het is mogelijk dat verbindingen die het complement systeem remmen hiervoor
verantwoordelijk zijn. Ook is het mogelijk dat een combinatie van verbindingen met een
verschillende werking nodig is om een onstekingsremmend effect in vivo te verkrijgen.
Kraakbeen geïnduceerde gewrichtsontsteking in muizen werd gebruikt als model om
een beeld te krijgen van de effecten van P. scrophulariiflora extracten op chronische
ontsteking. De behandeling met 200 mg/kg diethylether extract of 20 mg/kg apocynin
vertraagde de ontwikkeling van gewrichtsontsteking, hoewel geen van de geteste monsters
de ernst van de ontsteking verminderden. Deze resultaten suggereren dat apocynin
verantwoordelijk is voor de effecten van het diethylether extract op chronische
gewrichtsontsteking. Bovendien kan gesteld worden dat de remming van het diethylether
extract op het complement systeem, de chemiluminescentie en T cel proliferatie geen
voorspellende waarde hebben voor de remming van kraakbeen geïnduceerde
gewrichtsontsteking in muizen onder de onderzochte omstandigheden. De oorzaak hiervan
kan liggen in een te lage dosering, een slechte biologische beschikbaarheid, een ongunstig
farmacokinetisch profiel, of metabolische inactivering van werkzame componenten in vivo.
Het is ook mogelijk dat pathologische processen een rol spelen in het ontstaan van
chronische gewrichtsontsteking die niet zijn onderzocht of die onvoldoende worden
geremd door het diethylether extract. De in vivo effecten gingen niet gepaard met
belangrijke toxische effecten, zoals bleek uit de analyse van belangrijke immunologische
organen van muizen die gedurende 3 of 6 weken extracten van P. scrophulariiflora kregen
toegediend.
Verschillende methoden zijn gebruikt om op geleide van activiteit stoffen te isoleren
uit P. scrophulariiflora die interfereren met de klassieke route van het complement
systeem remmen. Een representatief overzicht van enkele methoden is weergeven in
hoofdstuk 6. Gedurende het onderzoek werd duidelijk dat zowel in het petroleumether als
het diethylether extract meerdere componenten aanwezig zijn die een effect hebben op
componenten van het complementsysteem. Het gehalte aan actieve verbindingen bleek
echter zeer laag wat isolatie en structuuropheldering onmogelijk maakte binnen het
beschikbare tijdsbestek. DLC analyse suggereerde echter de aanwezigheid van fytosterolen
in het petroleumether extract. Hoewel deze verbindingen niet eerder zijn aangetoond in
Picrorhiza soorten, komen fytosterolen algemeen voor in hogere planten en is hun
remmende werking op het complement systeem beschreven.
Hoofdstuk 7 beschrijft de isolatie van 2 cucurbitacinen uit de wortelstokken van P.
scrophulariiflora op geleide van groeiremming van humane T lymfocyten. Het
diethylether extract, dat een sterke remming vertoonde van celproliferatie, werd gescheiden
met behulp van Silica kolomchromatografie. Uit actieve fracties werd door kristallisatie
een zuivere actieve verbinding verkregen, deacetylpicracin. Andere actieve fracties werden
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vervolgens gescheiden met behulp van Sephadex kolomchromatografie, gevolgd door
HPLC, waardoor een tweede zuivere actieve verbinding werd verkregen, picracin. Een
derde actieve verbinding kon nog niet worden geïsoleerd. De structuur van beide
verbindingen werd opgehelderd door middel van meerdere massaspectrometrische en
NMR spectroscopische methoden. Beide componenten vertoonden een sterke remming van
T cel proliferatie. Nader onderzoek toonde aan dat deze effecten niet het gevolg waren van
direct toxische stoffen.
Mogelijke mechanismen werden onderzocht die aanleiding geven tot de waargenomen
effecten. Aangezien bij de proliferatie van T lymfocyten interleukine 2 (IL-2) een
belangrijke rol speelt, werd het effect van de geïsoleerde stoffen op de afgifte van IL-2
onderzocht. Incubatie van geactiveerde T cellen met picracin of deacetylpicracin vertoonde
een duidelijke remming van IL-2 afgifte. Dit effect kon eveneens niet worden
toegeschreven aan een direct cytotoxisch effect. Vervolgens werd onderzocht of de
remming van IL-2 afgifte het gevolg was van apoptose, ofwel geprogrammeerde celdood.
Flow cytometrische analyse van gemerkte cellen toonden aan dat picracin apoptose
induceerde in T lymfocyten, terwijl deacetylpicracin niet significant werkzaam was.
Bovendien bleek dat beide verbindingen een remmende werking hadden op de afgifte van
de ontstekingsmediatoren IL-1 en TNFα door geactiveerde monocyten. Deze stoffen
spelen een belangrijke rol in het ontstaan van chronische ontstekingen.
Beide verbindingen werden onderzocht in een diermodel voor vertraagd type
overgevoeligheid, een model voor onderzoek naar cellulaire immuunreacties. Zowel
picracin als deacetylpicracin vertoonden remming van de ontsteking na intraperitoneale
toediening. Lokale toediening veroorzaakte echter toename van de ontsteking. Controle
experimenten toonden aan dat met name picracin en in mindere mate deacetylpicracin een
dosis afhankelijke onstekingsreactie induceren in lage doseringen. Deze resultaten
suggereren een dualistisch effect van picracin en deacetylpicracin. Bij toediening in de
poot vertonen ze een plaatselijke immuunreactie, terwijl het mogelijk is dat ze na
systemische (i.p.) toediening worden omgezet in metabolieten die systemisch juist een
ontstekingsremmend effect hebben. Het is ook mogelijk dat de plaats van toediening
relevant is voor het waargenomen effect: wanneer er in de buikholte een depletie van
immuuncellen ontstaat als gevolg van apoptose, is het mogelijk dat vervolgens op een
andere plaats minder cellen beschikbaar zijn wanneer ter plekke een immuunreactie wordt
opgewekt.
Samengevat, het diethylether Soxhlet extract van gedroogde wortelstokken van
Picrorhiza scrophulariiflora een remmende werking heeft op de klassieke route van het
complement systeem, de afgifte van zuurstofradicalen of afgeleide verbindingen en de
proliferatie van T lymfocyten. Meervoudige toediening van dit extract aan muizen waarin
een acute lokale ontsteking was opgewekt resulteerde in een vermindering van de zwelling.
Bovendien vertraagde het extract de ontwikkeling van gewrichtsontsteking in muizen,
hoewel de ernst van de ontsteking niet werd beïnvloed. Activiteitsgeleide isolatie van het
diethylether extract resulteerde in 2 zuivere verbindingen die een remmend effect
vertoonden op de proliferatie van geactiveerde T lymfocyten. Beide verbindingen remden
de afgifte van IL-2 door deze cellen, en de afgifte van IL-1 en TNFα door geactiveerde
monocyten. Deze effecten zijn vermoedelijk het gevolg van het induceren van apoptose,
wat werd aangetoond door T lymfocyten te incuberen met picracin. De inductie van
apoptose speelt mogelijk ook een rol in de immuunmodulerende effecten in vivo.
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Geconcludeerd kan worden dat meerdere verbindingen een rol spelen in
immuunmodulerende effecten van Picrorhiza extracten. Picracin en deacetylpicracin
induceren een plaatselijke immuunreactie na lokale toediening, terwijl ze een remmend
effect hebben op een lokale onstekingsreactie na systemische (i.p.) toediening. Hoewel
deze laatste waarnemingen interessant zijn met het oog op de ontstekingsremmende
werking van Picrorhiza, kan niet worden uitgesloten dat deze verbindingen een lokale
ontsteking in de gewrichten verergeren. Het testen van picracin en deacetylpicracin in
experimenteel geïnduceerde gewrichtsontsteking kan hierover uitsluitsel geven. Hoewel
het diethylether extract waarin beide verbindingen aanwezig zijn het ontstaan van
gewrichtsontsteking in muizen vertraagt, zijn deze verbindingen niet noodzakelijk
verantwoordelijk voor dit effect. Aangezien een dergelijk effect werd aangetoond voor
apocynin, kan worden gesuggereerd dat apocynin verantwoordelijk is voor het
waargenomen effect van het diethylether extract op gewrichtsontsteking. Zowel het
diethylether extract als apocynin vertoonden echter geen effect op de ernst van de
gewrichtsontsteking in de onderzochte doseringen. Deze waarnemingen zijn in
overeenstemming met het feit dat in de traditionele geneeskunde het gebruik van
Picrorhiza bij de behandeling van gewrichtsontsteking niet is geïndiceerd en dat een
dergelijk gebruik volgens Āyurvedische principes juist moet worden afgeraden. Echter,
zowel de experimentele gegevens als de conclusies die getrokken zijn op basis van
onderzoek van de Āyurvedische principes suggereren dat Picrorhiza een belangrijke rol
kan spelen in het voorkómen van chronische gewrichtsontsteking.
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